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This thesis aims to study biomarkers in inflammation and infection, with a special focus on the distinction between infectious and non-infectious fever. The thesis consists of 
three parts, part I being this introduction, in which the concept of fever in infectious and 
non-infectious disease is discussed. Furthermore, in this part we provide an overview of the 
epidemiology of febrile disease, as studied both in a general hospital in the Netherlands and 
in a general hospital in Curaçao. Also, a review of current literature on biological markers in 
non-infectious fever is given. Part II describes our clinical studies with focus on biomarkers 
in different cohorts of patients with infectious and non-infectious fever. In part III, we sum-
marize the findings of this thesis and discuss future research.
Part i: introduction
In this part, a general introduction to the concept and pathophysiology of fever is given. To 
be able to discuss the diagnostic properties of biomarkers in inflammation and infection, it 
is of great importance to have good insight into the prevalence of febrile disease and diagno-
sis; the incidence and prevalence of a certain disease influence the diagnostic test properties, 
such as positive and negative predictive value. In this section, we describe the epidemiology 
and etiology of febrile disease in the emergency department (ED) both in the Netherlands 
and in Curaçao. As many cases of fever do not have an infectious etiology, we review current 
literature on biological markers as diagnostics in patients with non-infectious fever, with 
special attention to the biological marker procalcitonin (PCT).
Part ii: Biomarkers
This section focuses on biomarkers, suitable for discrimination between – bacterial - in-
fection and non-infectious inflammation. As a model of non-infectious inflammation, we 
studied the prognostic value of biomarkers during the acute phase response in rheumatoid 
arthritis. We present two emergency department studies – one in Amsterdam and one in 
Curaçao – investigating the diagnostic properties of currently used and new biomarkers, 
such as PCT and the long pentraxin 3 (PTX3). In addition, we studied the diagnostic behav-
ior of PCT in children with suspected H1N1-influenza during the 2009 pandemic.
Part iii: summary and aPPendices
In this part, we summarize the most important findings of our studies and we discuss future 
research. Data of a prospective pilot study on the ED, using PCT as a guide for antibiotic 
therapy, are presented.
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Fever as a symptom of disease is an ancient concept, with the oldest known reference dating back to the sixth century BC, when a pictogram of a flaming brazier, symbolizing 
fever and the local warmth of inflammation was used in Sumerian cuneiform inscriptions1. 
Several centuries later, Hippocratic physicians proposed that body temperature and homeo-
stasis in general was controlled by a delicate balance between four corporal humors - blood, 
phlegm, black bile and yellow bile -; fever was thought to be the result of an excess of yellow 
bile2.
During the Middle Ages, demonic possession was believed to be causing fever. By the 
18th century, after the development of improved microscopes by van Leeuwenhoek and the 
subsequent birth of microbiology, it was hypothesized that body heat was a result of fermen-
tation and putrefaction in the blood3. In the late 19th century, metabolic bodily processes 
were recognized as the source of fever, as well as the fact that tight control of temperature is 
essential for general well-being4. Further research in the 20th century has shown that differ-
ent endogenously produced molecules of leukocytic origin, such as interleukin 1 (IL-1), -2, 
6, tumor necrosis factor (TNF) and interferons (IFN), act on the thermoregulatory center 
of the hypothalamus, thus eliciting fever5.
Different definitions of fever for different purposes can be found. In clinical practice, a 
temperature greater than 38.0 ºC is considered fever, and fever is typically defined as a 
pyrogen-mediated rise in body temperature above this temperature. Physiologically, it has 
been defined as “a state of elevated core temperature, which is often, but not necessarily, 
part of the defensive responses of multicellular organisms (host) to the invasion of live 
(micro-organisms) or inanimate matter recognized as pathogenic or alien by the host”6. 
The elevated body temperature during fever should be distinguished from that occurring in 
hyperthermia. In fever, the rise in temperature is a result of well-controlled hypothalamic 
thermoregulation, whereas in hyperthermia the rise in body temperature is unregulated 
and pyrogenic cytokines are not directly involved, representing a failure of homeostasis7.
The function of fever is still under debate, with different studies showing both potentiating 
and inhibitory effects of the response to infection. Phylogenetic studies have shown that 
fever is widespread within the animal kingdom; as the rise in temperature is metabolically 
expensive but still is well-preserved in evolution, it has been argued that fever has to be 
an adaptive and beneficial response8. Furthermore, animal studies have demonstrated 
enhanced resistance to infection during experimentally increased temperature7. In human 
in vivo studies associations between higher temperatures and better disease outcome have 
been observed9-11. On the contrary, it has been suggested that pyrogenic cytokines such as 
IL-1, IL-2 and TNF are involved in at least part of the local and systemic response to infec-
tion, with higher levels of circulating cytokines correlating with less favorable outcome. 
In experimental studies, the adverse effects of gram-negative sepsis or lipopolysaccharide 
injections were attenuated by pre-treating animals with IL-1 antagonists and anti-TNF 
antibodies12, 13.
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Body temperature is controlled deep in the hypothalamus, where thermosensitive receptors 
are affected by blood temperature, as well as via direct neural connections that measure 
warmth and cold in skin and muscle. In addition to the peripheral temperature input, the 
hypothalamus possesses an independent circadian temperature rhythm oscillating around 
a steady setpoint, unaffected by ambient temperature. The hypothalamus interprets periph-
eral temperature information and compares this with the independent circadian rhythm, 
resulting in peripheral heat conservation or loss of heat production. During fever, the 
hypothalamic setpoint is reset to a higher level while the thermoregulatory mechanisms are 
still maintained5.
Substances causing fever, so-called pyrogens, can be divided into exogenous and endoge-
nous pyrogens. Most exogenous pyrogens are microbes, toxins or other microbial products, 
either working directly on the hypothalamus or inducing the release of endogenous pyro-
gens, derived form the host’s cells. Some endogenously produced molecules are also capable 
of inducing endogenous pyrogens, such as antigen-antibody complexes and complement 
factors. Endogenous pyrogens, most importantly IL-1, IL-6, TNF-α and IFN-γ, interact 
with brain microglia and brain endothelial receptors, thus activating the arachidonic acid 
pathway. This in turn results in the production of cyclo-oxygenase derived prostaglandins, 
prostacyclins and thromboxane. Prostaglandin E2, most notably, increases the hypotha-
Figure 1: Simplified pathogenesis of fever
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lamic thermostatic setpoint. As a result, efferent nerves are activated through sympathetic 
stimuli and vasoconstriction and heat conservation occurs5, 14, 15, 16.
Febrile illness is worldwide a very frequent cause of attendance at emergency departments 
(EDs). Fever was the third reported complaint among most frequently reported specific 
principal reasons for visiting an ED in the United States in 2005, accounting for 4.4 - 7.5 % 
of all ED consultations and for up to 30 % in non-surgical patients17, 18.
Although fever is often caused by bacterial, viral or parasitic infections, an elevated 
body temperature can be observed in many non-infectious diseases, such as auto-immune 
diseases, malignancies and thrombo-embolic processes. Distinction between causes of 
fever is clinically important, because infectious fever will be treated with antibiotics or anti-
viral medication, whereas non-infectious fever might be treated with immunosuppressive 
drugs. Although major breakthroughs have been observed in the treatment and prevention 
of infections over the past decades, tools for discriminating between infectious and non-
infectious causes of fever – either physical examination or supplemental diagnostics - are 
still very inaccurate and non-specific19-21.
In order to gain better insight in the epidemiology of fever at the first aid department, 
we investigated two patient cohorts with non-surgical fever, one at a general hospital in 
Amsterdam, the Netherlands, and one in a general hospital in Curaçao, a subtropical South-
American island close to the coast of Venezuela. In both cohorts, as expected, most patients 
were diagnosed with a bacterial infection and were treated with antibiotics. Infection could 
be confirmed in approximately 40% of the patients; approximately 80% of these patients 
were diagnosed with a confirmed bacterial infection. Leading causes of bacterial infection 
were pneumonia and urinary tract infections. Approximately 5% of patients with confirmed 
infection had a viral disease; parasitic or fungal disease was diagnosed in 1.4% and 10.0%, 
respectively. Non-infectious fever was diagnosed in 4.2% en 5.2% of patients, respectively. 
Mortality in both cohorts was substantial, 4.2% and 7.9%, respectively. Patient characteris-
tics are given in table 1 (Slotervaart Hospital, Amsterdam, the Netherlands) and table 2 (St. 
Elisabeth Hospital, Curaçao). Most reported diagnoses are given in figures 1 and 2.
Table 1: patient characteristics Slotervaart Hospital
n = 213
n (%) / median (IQR)
Sex, female 111 (52.1)
Age, yrs. 66 (46 – 79)
Hospitalization 187 (87.8 %)
Admission to Intensive Care Unit 18 (8.5 %)
Mortality 9 (4.2 %)
IQR = interquartile range
18
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Table 2: patient characteristics St. Elisabeth Hospital
n = 403
n (%) / median (IQR)
Sex, female 196 (49)
Age, yrs. 52 (32 – 71)
Hospitalization 223 (55.6 %)
Admission to Intensive Care Unit 18 (4.5 %)
Mortality 32 (7.9 %)
IQR = interquartile range
Figure 3: Most reported final diagnosis of febrile patients at the Emergency Department of the St. Elisabeth 
Hospital, Curaçao, during the year 2008 (UTI: urinary tract infection; NOS: not-otherwise specified)
Figure 2: Most reported final diagnosis of febrile patients at the Emergency Department of the Slotervaart Hospital, 
Amsterdam, the Netherlands, during the year 2008 (URTI: upper respiratory tract infection)
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These two epidemiological studies show that fever in patients at the ED is mainly caused 
by bacterial infection, but that a substantial part of patients suffer from a non-infectious 
febrile disease. Moreover, in these patient populations, high mortality numbers are ob-
served. No data on incidence of non-infectious fever at the ED have been published before. 
The incidence of infectious fever we show, however, is comparable to that found in other 
studies17, 18; we assume that our findings can be extrapolated to other hospitals worldwide, 
particularly because, despite substantial differences in health care setting, population and 
climate, results are quite equal between the two investigated hospitals.
The search for new and better biomarkers that predict the presence of bacterial infection 
in febrile patients has become increasingly relevant, particularly in view of rising antibiotic 
resistance and medical costs worldwide. Currently used biomarkers, such as C-reactive 
protein (CRP) have repeatedly been shown to be not sensitive or specific enough to discern 
between different causes of fever20.
Recently, use of several new biomarkers for this purpose has been studied. Among many 
potential markers, procalcitonin (PCT) - a prohormone of calcitonin, under physiological 
conditions produced by the thyroid gland - appears to be a promising and specific marker of 
bacterial infection in different patient groups and conditions, varying from neonatal sepsis 
to outpatients with respiratory complaints. As has been repeatedly shown, procalcitonin 
has a high specificity (ranging from 90-98%) for predicting bacterial infections and would 
therefore, theoretically, be suitable for the discrimination between patients with bacterial 
fever and patients with underlying non-infectious febrile disease22-25.
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aBstract
Fever is not only observed in the course of a bacterial or viral infection, but can be a symp-
tom of, for instance, auto-immune, malignant or thromboembolic disease. Determining 
the etiology of fever in a fast and reliable way is of pivotal importance, as different causes of 
fever may ask for different therapies. Neither clinical signs and symptoms, nor traditional 
biomarkers, such as CRP, leukocytes and ESR have sufficient sensitivity and specificity to 
guide treatment decisions. In this review we focus on the value of traditional and newer 
biomarkers in non-infectious febrile diseases. Procalcitonin (PCT) seems to be the most 
helpful laboratory marker for the differentiation of causes of fever, particularly in autoim-
mune, autoinflammatory and malignant diseases.
Keywords: fever, biological markers, autoimmune diseases, C-reactive protein, procalcito-
nin.
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introduction
Fever is one of the most frequent symptoms seen in patients by both family doctors and 
in the emergency departments of hospitals. Fever is the third leading cause of visits to an 
emergency department in the United States; approximately 10% of emergency patients are 
prescribed antibiotics1.
Besides infections - bacterial, viral or parasitic – there are several non-infectious medi-
cal conditions that can cause an elevated body temperature. Fever is observed in systemic 
diseases such as systemic lupus erythematosus and rheumatoid arthritis, in inflammatory 
bowel diseases, in auto-inflammatory syndromes, as a paraneoplastic phenomenon in ma-
lignancy or during neutropenia after chemotherapy, as a result of tissue loss in ischemic or 
thromboembolic processes, in endocrine disorders and as a result of medication.
During the past 10 years, the interest in biomarkers that discriminate between infectious and 
non-infectious causes of fever has grown. Moreover, the need for new and better biomarkers 
that predict the presence of bacterial infection in febrile patients has become increasingly 
relevant. ESR has now been used clinically for almost 90 years, whereas C-reactive pro-
tein (CRP) has been used routinely for the past 30. It has repeatedly been shown that the 
clinically often-used CRP is part of an intrinsically, non-specific acute phase reaction and 
is therefore not sensitive or specific enough to discern between different causes of fever. 
The same holds true for other traditional biomarkers. Although major breakthroughs have 
been observed in the treatment (antibiotics) and prevention (vaccines) of infections during 
the past decades, tools for discriminating between infectious and non-infectious causes of 
fever are still very inaccurate and non-specific2-4. When treatment is started, currently used 
laboratory markers are of limited value regarding the guidance of treatment. Finally, a new 
generation of biomarkers is on the verge of clinical introduction.
Figure 1: Time course of induction of various parameters of the systemic inflammatory system after stimulus 
(thoracic surgery). Concentrations are relative and adapted to the Y-axis. Figure courtesy of M. Meisner, 1999, 
adjusted with permission.
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Discriminating between an infectious or non-infectious origin of a fever is of major im-
portance, because the former can be treated with antibiotics, whereas the latter might call 
for strong, immunosuppressive drugs. An ideal biomarker would have a sensitivity and 
specificity of 100%, providing the treating physician with certain knowledge about the cause 
of the fever.
Recently, several studies focusing on new markers, have been undertaken. Procalcitonin 
(PCT) is such a new marker, about which a number of clinical studies have been published. 
PCT is a specific marker of bacterial infection in different patient groups and conditions, 
varying from neonatal sepsis to outpatients with respiratory complaints5-12. After a bacterial 
stimulus in healthy volunteers, PCT levels rise within 4 hours, reaching peak levels after 6 
hours and maintaining a plateau through 8 and 24 hours13 (figure 1).
PCT has a half-life time of approximately 24 hours, independent of renal function14.
As has been repeatedly shown, procalcitonin in general has a high specificity (ranging 
from 90-98%) for bacterial infections 7, 8, 11, 15 and would therefore, theoretically, be suitable 
for the discrimination of bacterial fever in patients with underlying non-infectious febrile 
disease. However, slightly elevated PCT levels can be observed 3-24 hours after aerobic ex-
ercise16 and not all bacterial infections give rise to elevated PCT levels5. Moreover, although 
the negative cut-off value for PCT is generally believed to be < 0.5 ng/mL, optimal cut-off 
points vary between different studies and patient populations. A mild increase of PCT val-
ues could be observed in some patients with an inflammatory, non-infectious condition17.
The general departure point in the majority of earlier studies, that focus on circulating 
levels of biomarkers in febrile patients, is infection. In this review we describe, for the first 
time, the diagnostic applicability of traditional laboratory markers, procalcitonin and other 
promising biomarkers, taking non-infectious febrile diseases as a departure point. It is 
particularly within this interesting subgroup of fever patients, who, as a result of the lack of 
objective parameters to guide the prescribed treatment, are likely to receive antibiotics if the 
treating physician has reason to doubt the etiology of the fever. Biomarkers with a higher 
test sensitivity and specificity, regarding the discrimination between fevers with infectious 
and non-infectious causes, will reduce the amount of antibiotic prescriptions in this patient 
group and thus lead to a reduction in costs and the development of resistant bacterial strains.
The distinction between viral and bacterial infection, as well as fevers caused by the use 
of medication, are beyond the scope of this article.
Search terms were “Biological markers [MeSH]”, “Fever [MeSH]”, “C-reactive protein 
[MeSH]”, “Blood sedimentation [MeSH]”, “Procalcitonin [MeSH]”, “Serum Amyloid Pro-
tein A [MeSH]”, “PTX3 Protein [MeSH]”, “Autoimmune Diseases [MeSH]”, “Inflammatory 
Bowel Diseases [MeSH]”, “Periodic fever syndromes”, “Neoplasms [MeSH]”, “Neutropenia 
[MeSH]”, “Ischemia”, “Thrombo-embolism”, “Endocrine System Diseases [MeSH]”, “Diag-
nosis” and “NOT infection”. Non-English articles and non-human studies were excluded 
from this review.
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autoimmune and non-infectious inflammatory diseases
Autoimmune disease is defined as a disease with proof of direct transmissibility of the 
characteristic lesions of the disease from human to human or from human to animal – i.e., 
demonstrating the direct pathological effect of autoantibodies -; by indirect re-creation 
of human disease in an animal model; or by circumstantial evidence such as a positive 
family history, presence of other autoimmune phenomena in the same patient, infiltrat-
ing mononuclear cells in affected tissue, preferential use of certain MHC-II alleles, high 
serum levels of IgG autoantibodies, deposition of antigen-antibody complexes in affected 
tissue and/or improvement of symptoms with immunosuppressive therapy18. However, 
in many diseases it remains difficult to prove autoimmunity. Ongoing research has led to 
the insight that in some of the diseases that were originally categorized as autoimmune 
diseases – for instance, sarcoidosis, Behcet’s disease and temporal arteritis -, the role of 
auto-antibodies in the pathophysiology was overestimated. These disorders are nowadays 
coined as non-infectious inflammatory syndromes, with the autoinflammatory disorders as 
a well-circumscribed subgroup.
Patients suffering from systemic diseases such as rheumatoid arthritis, systemic lupus 
erythematosus or vasculitides are prone to infection, particularly during immunosup-
pressive therapy19. As most auto-immune and non-infectious inflammatory diseases are 
characterized by fever, the differentiation of infection from active systemic disease is often 
difficult, but it has important clinical consequences.
For decades, rheumatologists have been using the erythrocyte sedimentation rate (ESR) as 
an indicator of activity of autoimmune disease and infection. However, during the past 20 or 
so years, the value of using ESR has been questioned, as sensitivity and specificity numbers 
vary strongly between different studies and diseases. ESR is not helpful in discriminating 
between active autoimmune disease and infection20. The only reliable use of ESR seems to 
be in the diagnostic process of temporal arteritis, where a low ESR gives a high negative 
predicting value21.
CRP, although widely used as an early and sensitive marker of infection and inflammation, 
is not sensitive enough to discriminate between infectious episodes or the exacerbation of 
an underlying autoimmune disease. Although values of CRP are generally intermediate to 
low in patients with active SLE, it is not possible to differentiate between SLE activity and 
infection as a cause of fever, based on CRP alone22-24. Patients with SLE and serositis show 
elevated CRP levels. However, elevated CRP levels in SLE patients without clinical signs of 
serositis are generally assumed to be indicative of bacterial infection25.
Persistent elevations of circulating IL-6 levels have been shown to be associated with 
outcome in different patient groups26. However, despite fast and relatively high peak values 
during acute phase response, interleukin-6 (IL-6) has no additional value over CRP in 
discriminating systemic infection from absence of infection in patients with SLE, as plasma 
IL-6 concentrations are elevated in a significant amount of patients with autoimmune dis-
eases in the absence of infection24.
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Serum amyloid A (SAA) has the same initial kinetics as CRP in the acute phase re-
sponse, with a less rapid decrease after initial elevation. Elevated serum levels of SAA have 
been described in a wide variety of diseases, including rheumatoid arthritis, ankylosing 
spondylitis, Behcet’s syndrome and Crohn’s disease27.
No studies using SAA as a marker for distinction between infectious and non-infectious 
fever have been undertaken. Due to the shared acute phase pattern with CRP and its longer 
half life, it is not to be expected that SAA is a helpful marker for this purpose. SAA may 
be useful in the evaluation of therapy response and the determination of progression to 
amyloidosis in these patient groups28-30.
PCT seems to be a promising marker in differentiating between autoimmune-induced 
fever and infectious-bacterial fever. Strongly elevated PCT levels have been observed in 
several systemic and localized bacterial infections5, 6, 15, 24. PCT appears to have a higher 
specificity for bacterial infection than other markers, although it is apparent that not all 
patients with bacterial infection have elevated PCT levels5.
In a cohort of patients with Wegener’s granulomatosis, elevated PCT levels were described 
in those suffering from bacterial infection, whereas PCT levels were normal in patients with 
active autoimmune disease. In the same cohort, CRP could not be used for differentiation 
purposes23. In a study in patients with active Behcet’s disease, PCT values were not elevated, 
whereas CRP and IL-6 levels were higher, when compared to healthy controls31. PCT values 
in patients with diverse systemic autoimmune diseases accompanied by infectious fever were 
elevated, when compared to values in patients with systemic autoimmune diseases and non-
infectious fever32. Circulating PCT levels in patients with early RA and reactive arthritis were 
shown to be normal, whereas PCT levels in patients with bacterial sepsis were elevated 33.
Recent preclinical in vitro studies focus on glyco-biomarkers and vascular endothelian 
growth factor (VEGF). In rheumatoid arthritis (RA), glyco-biomarkers have been proposed 
as future markers for diagnosis and prognosis. Glyco-biomarkers are sugar molecules 
that are an integral feature of nearly all biomolecules; they may represent a way in which 
immunotolerance can be bypassed. IgG-G0 (IgG-agalactosyl) may be a diagnostic and 
prognostic marker in RA, with levels of IgG-G0 exhibiting a correlation with the severity 
and duration of the disease. The relationship between glycosylation and infection still has 
to be elucidated34.
Serum levels of VEGF correlate well with RA disease severity and swollen joint counts. 
VEGF might play an important part in the establishment and promotion of RA and might 
serve as a marker for disease activity, with a more active disease being associated with 
higher serum levels35.
autoinflammatory diseases
The autoinflammatory diseases are a heterogeneous group of hereditary syndromes char-
acterized by seemingly unprovoked periodic episodes of inflammation without high titers 
of autoantibodies or antigenspecific T lymphocytes and in the absence of infection36. A 
central role for proteins with a PYRIN domain has been suggested. In normal states, pyrin 
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downregulates activity of a caspase recruitment domain which promotes elevated levels of 
IL-Iβ and NF-κB. In autoinflammatory disease, this downregulation is affected, resulting in 
the production of IL-Iβ and eventual inflammation36. Major autoinflammatory syndromes 
are familial Mediterranean fever (FMF), hyperimmunoglobulinemia D and periodic fever 
syndrome (HIDS) and tumor necrosis factor receptor superfamily 1A-associated periodic 
syndrome (TRAPS). Adult onset Still’s disease, although in contrast with other autoinflam-
matory syndromes non-hereditary, associated with longer exacerbations and with possible 
bone and cartilage destruction, may be classified as an autoinflammatory syndrome as it 
leads to comparable clinical features, in the absence of evidence for a link to microorgan-
isms or circulating auto-antibodies37. Similar to other chronic inflammatory diseases, yet 
significantly more prevalent, the most severe complication of autoinflammatory syndromes 
is amyloidosis, leading to end-stage renal failure38.
Susceptibility genes in most of the autoinflammatory diseases have been identified and 
insight in molecular pathogenesis has improved. This has led to better diagnosis and more 
rational therapy, with a growing interest in biological therapy with anti-TNF and anti-IL-I 
agents39. However, only a few studies have focused on the acute phase response during 
exacerbations of autoinflammatory diseases, with evidence for marked elevations of CRP, 
the long pentraxin 3 (PTX3), serum amyloid A protein and IgD levels40-42.
Attacks of FMF can be severe and may mimic acute abdominal syndromes such as 
appendicitis or pelvic inflammatory disease so closely, that abdominal surgery can be mis-
takenly performed. A major challenge in the treatment of FMF patients, in particular, is to 
distinguish FMF attacks from infectious disease. One study showed that levels of CRP and 
PTX3 were increased during an FMF attack, whereas PCT was elevated above normal cut-
off values in only 2 out of 22 patients43. Thus, PCT may be a promising marker to distinguish 
infectious disease from sterile FMF attacks.
In a study comparing PCT values in patients with adult onset Still’s disease with and 
without infectious fever, high levels of PCT were also observed in patients without bacterial 
infection, indicating that PCT is not useful for the differentiation between exacerbations of 
Still’s disease and infection32. High levels of serum ferritin are a common finding in Still’s 
disease. Glycosylated ferritin, in non-pathological conditions representing more than half 
of the total serum ferritin, is often very low (< 20%) in adult onset Still’s disease, while the 
level is higher (20-50%) in other inflammatory conditions. However, also during severe 
systemic infections, glycosylated ferritin levels < 20% can be found44.
inflammatory bowel diseases
The two major inflammatory bowel diseases (IBD) are ulcerative colitis and Crohn’s disease. 
Both diseases are treated with corticosteroids and immune modifying agents, resulting in 
a relatively immune compromised state. Patients with IBD are particularly susceptible to 
Clostridium difficile infection and have a four times higher chance of dying as a result of 
infection than patients without IBD45.
The pathogenesis of IBD has still to be elucidated. A cascade of immunologic events 
occurs, resulting in increased local release of pro-inflammatory cytokines in the gut. Il-
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6, IL-10 and TNF-α, in particular, have been shown to play a pivotal role in the chronic 
inflammatory process46,  47. As ulcerative colitis and Crohn’s disease are different disease 
entities both clinically and pathophysiologically, different acute phase responses during 
exacerbations can be expected. However, the scarce research addressing the differentiation 
between exacerbations of IBD and infectious colitis does not focus on ulcerative colitis and 
Crohn’s disease separately. Hence, in this review we are forced to consider the two diseases 
as one group.
As diverse cytokines are produced in large amounts during exacerbations of IBD, levels 
of regularly used laboratory markers such as CRP or ESR will be elevated, and they therefore 
possess little discriminatory value48. However, an accumulation of evidence points towards 
an association between oxidative stress and exacerbations. Markers for lipid peroxidation 
and antioxidant status have been shown to be higher in patients with active IBD, indicating 
enhanced oxidative stress and decreased anti-oxidant status49. There is a proven correlation 
between oxidative stress and the severity of sepsis; in non-septic infections the levels of 
oxidative stress should be low50. Emergency patients with bacterial infection were shown to 
have normal markers for oxidative stress51. A combination of elevated acute phase proteins 
and normal markers for oxidative stress suggests the presence of infection in patients with 
IBD, whereas an exacerbation of IBD might be indicated by elevated acute phase proteins 
and markers for oxidative stress. As a complicating factor, patients suffering from Chronic 
Granulomatous Disease (CGD) - a rare disorder caused by defects in the phagocyte NADPH 
oxidase resulting in the inability to generate reactive oxygen intermediates - may present 
with a clinical picture mimicking Crohn’s disease52, which makes a pathogenic role for 
oxidative stress less likely.
One study assessed the value of PCT in a cohort of 51 IBD patients and 25 patients with 
self-limiting colitis. All IBD patients exhibited low levels of PCT in serum, independent of 
disease activity, whereas patients with infectious colitis were shown to have elevated PCT 
values. In this study the positive, predictive value for diagnosing infectious colitis was 96%, 
with a negative predictive value of 93%53.
malignant disorders
Neoplasms contribute to between 7-20% of the cases of fever of unknown origin54, 55. Fever 
is particularly associated with non-Hodgkin lymphoma, leukemia, renal cell carcinoma 
and hepatocellular carcinoma. Although the pathophysiology of neoplastic fever is not well 
understood, it is suspected to be cytokine mediated, with emphasis on IL-1, IL-6, TNF-α 
and interferon. It has been suggested that tumor cells produce pyrogens; another proposed 
explanation for neoplastic fever is the release of TNF by necrotic bone marrow. In neutro-
penic patients receiving chemotherapy, the discrimination between neoplastic fever and 
infectious fever is essential55.
The value of CRP in differentiating infectious from non-infectious fever in neutropenic 
patients has been studied extensively. It has repeatedly been shown that CRP is an unreliable 
marker of bacterial infection in this patient group56-58.
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A recent systematic review identifies PCT as a valuable tool in determining the etiology 
of fever in neutropenic patients, with elevated levels of circulating PCT in patients with 
bacterial fever10. One study comparing the value of PCT, neopterin, CRP, IL-6 and IL-8 as 
diagnostic markers for this purpose showed a high, negative predictive value of PCT for 
Gram-negative bacteremia and non-significant results for the other markers9. It has been 
argued that a risk-assessment model, including clinical parameters together with laboratory 
markers such as PCT or IL-8, should be constructed, thus enabling physicians to accurately 
define a low-risk group of febrile neutropenic patients59.
ischemic diseases
During the first days after myocardial fever, low grade fever is a common observation. A 
relationship between the extent of necrosis and the rise in temperature has been shown60, 61. 
Animal studies indicate that elevated corporal temperature might be harmful prior to and 
directly after an acute coronary syndrome or myocardial infarction62. Fever after myocardial 
tissue loss occurs due to ischemic cell death, resulting in the production of cytokines. TNF, 
a very potent inflammatory mediator, has been shown to be present to an excessive degree 
in plasma during this process63.
In patients who have suffered an acute stroke, fever is also a common observation. 
Although approximately 25% of patients who have suffered an acute stroke and fever suffer 
from concomitant infection, about 15% of patients have a fever without a recorded infection. 
Fever in this patient group is associated with poor outcome and severe cerebrovascular 
damage. A correlation between cerebral tissue loss and fever has been noted. The only 
discriminating characteristic between the infectious and non-infectious causes of fever is 
the early onset of fever in non-infectious patients64, 65.
No clinical studies, investigating the role of biomarkers in differentiating between infec-
tious and non-infectious etiology of fever in patients suffering from myocardial infarction 
or acute stroke, have been undertaken.
Fever is observed in a substantial number of patients with pulmonary embolism (PE). 
The exact etiology of this fever is unclear. However, similar cytokine cascades as in true 
ischemic conditions may be expected66. Based on ESR and leukocyte counts, no differentia-
tion between PE and community acquired pneumonia can be made67. One study assessed 
the value of PCT in patients with possible PE. Out of 40 patients with fever and clinical and 
radiological findings consistent with pleuritis or pneumonia, 10 patients were diagnosed 
with PE and 30 with pneumonia. But while high CRP levels were measured in these 10 
patients, PCT levels were normal68. These findings need to be confirmed within the context 
of a larger trial.
endocrine disorders
Phaeochromocytoma is classically associated with spiking fever. In some phaeochromocy-
tomas, a central role for IL-6 can be observed. Based on laboratory markers, phaeochromo-
cytoma may be difficult to distinguish from an abscess, for instance, as the elevation of IL-6 
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is followed by a general inflammatory reaction. High levels of leukocytes, fibrinogen and 
CRP will be observed69.
In acute adrenal insufficiency, fever is one of many aspecific findings. It is unclear 
whether this fever is indicative of general inflammation or whether it is due to the pre-
cipitating infection that is most often the direct cause of adrenal insufficiency70. As most 
cases occur after infection, and patients are likely to develop severe shock, initial empirical 
antibiotic treatment is warranted. No studies that try to discriminate between infectious and 
non-infectious causes of acute adrenal insufficiency have been undertaken. This is because 
treatment should not be delayed while diagnostic tests are performed.
To our knowledge, procalcitonin has not been evaluated in endocrine disorders.
conclusion
In this review we have described the value of commonly used biomarkers, procalcitonin, 
and other experimental markers in patients with non-infectious fever. Fever is a very com-
mon symptom of many diseases, reflecting general inflammatory processes in the body that 
are not necessarily caused by infection. The proper treatment of febrile patients requires 
adequate and quick diagnoses. Laboratory markers with high sensitivity and specificity 
regarding the differentiation between infectious and non-infectious causes of fever may 
Table 1: Differential diagnosis of non-infectious febrile diseases and relative values of CRP and PCT during steady 
state, exacerbation of underlying disease and bacterial infection (no change from baseline indicated by “=”, relative 
elevation from baseline indicated by “↑” or “↑↑”, insufficient data indicated by “??”)
Steady state Exacerbation Bact. infection
Auto-immune/systemic CRP PCT CRP PCT CRP PCT
· RA = = ↑ = ↑↑ ↑↑
· SLE = = =/↑ = ↑↑ ↑↑
· Arteriitis temporalis ↑/↑↑ = n/a n/a n/a n/a
· Vasculitis other =/↑ = =/↑↑ = ↑/↑↑ ↑/↑↑
· Sarcoidosis =/↑ ?? =/↑ ?? ↑/↑↑ ??
· Behcet’s = = ↑ = ↑/↑↑ ↑/↑↑
Auto-inflammatory
· FMF = = ↑↑ =/↑ ↑/↑↑ ↑/↑↑
· TRAPS/HIDS = ?? ↑↑ ?? ?? ??
· Still’s disease = = ↑↑ ↑↑ ↑/↑↑ ↑/↑↑
IBD
· Crohn’s disease = = ↑/↑↑ = ↑/↑↑ ↑/↑↑
· Colitis ulcerosa = = ↑/↑↑ = ↑/↑↑ ↑/↑↑
Malignancy =/↑↑ = n/a n/a =/↑↑ ↑/↑↑
 Tissue loss/ ischemia ?? ?? ?? ?? ?? ??
Endocrine ?? ?? ?? ?? ?? ??
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support the treating physician in deciding to withhold the prescription of antibiotics, thus 
leading to cost reductions and the decrease of bacterial resistance.
Traditional biomarkers, such as CRP, leukocytes and ESR do not have sufficient sensitiv-
ity and specificity to guide treatment decisions. To date, PCT seems to be the most helpful 
laboratory marker for this purpose, particularly in autoimmune, autoinflammatory and 
malignant diseases. PCT is not useful for the differentiation between exacerbations of Still’s 
disease and infection (Table 1).
PCT has recently been introduced as a clinical marker in various hospitals all over the 
world, and is more and more accepted as a useful marker in the diagnostic process in febrile 
patients. However, the optimal cut-off values for PCT in different patient groups with differ-
ent pathology still have to be constructed. At this moment, the PCT assay is still costly with 
a range of $ 20,- to $ 40,- per measurement, which makes it less suitable for resource-poor 
countries.
Other novel biomarkers, such as SAA and PTX3, are still experimental; further research 
on these markers is required to determine their clinical value.
It should be clear that no single biomarker is sensitive or specific enough to be relied on 
completely. Therapy decisions should still be based on a combination of medical history, 
physical examination and adjunctive tests. In specific cases, specific biomarkers can be used 
to discriminate infectious from non-infectious fever. Further research in specific patient 
groups should focus on integrating biological markers and clinical parameters into decision 
rules. As the usefulness of laboratory markers varies within different diseases, decision rules 
applicable to specific settings and diseases have to be developed.
Despite the added value of procalcitonin and other “new kids on the block”, medicine 
still remains the science of uncertainty and the art of probability.
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The acute phase response is not predictive for rheumatoid arthritis
aBstract
introduction
In clinically active rheumatoid arthritis (RA) acute phase reactants such as C-reactive 
protein (CRP) can be elevated. Patients presenting with arthralgia and a positive test for 
anti-cyclic citrullinated peptide antibodies (aCCP) and/or IgM rheumatoid factor (IgM-RF) 
are at risk for developing RA. Elevated acute phase reactants in this phase could be predic-
tive for the development of arthritis.
methods
137 aCCP and/or IgM-RF positive patients were included. Patients were followed annually 
for the development of arthritis, which was defined as presence of one or more swollen joints 
at clinical examination. High sensitive CRP (hsCRP), Procalcitonin (PCT), SPLA2, Tumor 
necrosis factor (TNF)-α, IL-6, IL-12p70, IL-10 and interferon (IFN)-γ were measured in 
baseline serum samples. Gene expression focusing on a predefined panel of genes coding 
for inflammatory molecules was measured by means of multiplex ligation-dependent probe 
amplification (MLPA).
results
35 patients (26 %) developed arthritis within a median time of 11 months (IQR 3.7 – 18 
months). Circulating levels of cytokines, sPLA2, hsCRP and PCT were not different between 
patients with progression to clinical arthritis and patients without progression. However, a 
trend for IL12p70, TNF-α, IL-10, IL-6 and sPLA2 could be observed. No significant correla-
tion between mRNA expression levels of inflammatory genes was found. Subgroup analysis 
of patients with early progression to arthritis showed significantly higher levels of mRNA 
expression of PARN and BMI1 as compared to patients without progression to arthritis.
conclusions
Although low grade inflammation is present before the onset of clinical arthritis in large 
cohorts and can be detected using consecutive measurements, a single measurement of 
acute phase reactants seems to be of limited value for prediction of development of arthritis 
in individual patients.
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introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease, of which the exact 
etiology remains to be elucidated. In the pathophysiology of RA, inflamed synovia play 
a central role, exhibiting varying changes with disease progression. In early, pre-clinical 
disease, hyperplasia and edema of synovial lining can already be observed. The synovial 
sublining is infiltrated by mononuclear cells, mainly macrophages and monocytes, T cells 
and B cells, producing cytokines and chemokines including IL-1, IL-6 and TNF-α. In clini-
cally active RA, inflammation is represented in the blood by elevated levels of acute phase 
reactants such as high sensitivity C-reactive protein (hsCRP), which can thereby be used as 
a diagnostic marker for disease activity.
Approximately half of patients with RA have specific serologic abnormalities sev-
eral years before the onset of symptoms. The presence of an elevated serum level of IgM-
Rheumatoid factor (IgM-RF) or anti citrullinated peptide antibodies (ACPA) in a healthy 
individual implies an increased risk for the development of RA1. Furthermore, a rise in CRP 
and secretory phospholipase A2 (SPLA2) levels has been associated with the development of 
RA2. However, it remains unclear whether these serological markers can be used to predict 
the development of arthritis prior to disease onset.
This study was conducted to test the hypothesis that acute phase proteins can be used as 
markers to predict the development of RA in patients at increased risk.
Patients and methods
study population
The study was conducted at the Jan van Breemen Research Institute, Reade, Amsterdam. 
A detailed description of the study population can be found in previous publications3,  4. 
In short, patients with arthralgia and a positive anti-CCP2 and/or IgM-Rheumatoid Fac-
tor (IgM-RF) status were recruited. At the first visit, a trained investigator completed a 
questionnaire regarding the presenting symptoms. The absence of arthritis was confirmed 
by two independent investigators (WB or LAS and DS) of which one was a senior rheuma-
tologist blinded for antibody status and medical history. Patients were excluded if one or 
both investigators observed any swollen joint and/or if chart review revealed past arthritis 
observed by a rheumatologist. Furthermore, patients previously treated with a disease 
modifying anti-rheumatic drug (DMARD) and patients with systemic lupus erythema-
tosus or Sjögren’s  syndrome were excluded due to the possibility of false-positive RF in 
these patients. During yearly follow-up visits, development of arthritis was independently 
confirmed by two investigators (WB or LAS and DS). Extra visits were planned if arthritis 
developed. Median follow-up was 21 months (range 6–48 months). Analysis for the current 
study started after inclusion of the first 137 consecutive patients from this cohort, recruited 
between September 2004 and November 2007.
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Furthermore, 20 patients with RA fulfilling the 1987 ACR criteria were selected as a 
positive control for hsCRP and SPLA2 measurements and 40 healthy blood bank donors 
were used as negative control.
measurements
Blood samples were obtained by venapuncture. RNA was isolated from PAXgenetm tubes 
(PreAnalytiX GmbH, Hombrechtikon, Switzerland) containing RNA stabilizing buffer 
according to protocol and gene expression was measured by means of multiplex ligation-
dependent probe amplification (MLPA), focusing on a predefined panel of genes coding 
for inflammatory molecules, as described previously5. EDTA anticoagulated plasma was 
aliquoted and stored at -80°C. The blood was routinely screened for haematological and 
biochemical variables. hsCRP was measured using a highly sensitive latex-enhanced assay 
on a Hitachi 911 analyzer (Roche Diagnostics), according to the manufacturer’s instructions. 
Procalcitonin (PCT) levels were measured by a chemiluminescence sandwich immunoassay 
(BRAHMS AG, Hennigsdorf, Germany) as previously described6. SPLA2 levels were mea-
sured by ELISA as previously described7. Tumor necrosis factor (TNF)-α, IL-6, IL-12p70, 
IL-10 and interferon (IFN)-γ were measured by cytometric bead array (CBA) multiplex 
assay (BD Biosciences, San Jose, CA, USA). All samples were measured in a blinded fashion 
without knowledge of the clinical status of the patients.
statistical analysis
Baseline demographic and clinical variables are tabulated and descriptive statistics are 
presented as numbers with percentages, medians with inter quartile ranges (IQR) or means 
with standard deviations when a normal distribution could be assumed.
Differences in marker levels between groups were determined with an unpaired T-test. 
Correlations were determined by means of logistic regression analysis. CBA, MLPA and 
biomarker levels were transformed with their natural logarithm prior to statistical analysis 
to normalize the data.
Subgroup analysis comparing early progressors, defined as patients with development 
of arthritis within the first IQR after inclusion in the study, with non-progressors was per-
formed for all markers. A two-tailed p-value <0.05 was considered to indicate statistical 
significance.
results
Patient characteristics
137 Anti-CCP and/or IgM-RF positive arthralgia patients were included. Patient character-
istics are shown in table 1. Among the patients, 82 (60%) were IgM-RF positive, 94 (69%) 
were anti-CCP positive and 39 (29%) were both IgM-RF and anti-CCP positive. Overall, 35 
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patients (26 %) developed arthritis within a median time of 11 months (IQR 3.7 – 18 months); 
18 patients developed arthritis within the first IQR after inclusion and were considered early 
progressors.
circulating levels of cytokines
Circulating levels of cytokines were not different between patients with progression to clini-
cal arthritis and patients without progression. However, a trend for IL12p70, TNF-α, IL-10 
and IL-6 could be observed, with higher levels in patients who progressed to arthritis (p = 
0.07, p = 0.07, p = 0.10 and p = 0.05, respectively). Subgroup analysis of circulating levels 
of cytokines in early progressors as compared to patients without progression to arthritis 
showed no significant difference (see Table 2).
mrna biomarkers
No significant correlation between mRNA expression levels of inflammatory genes - 
TNF–α, IL-1β, IL-1RA, IL-8, IL-15, nuclear factor (NF)-κB1A, NF-κB1, serpin B9, MYC, 
cyclin-dependent kinase inhibitor 1A (CDKN1A), small inducible cytokine A4 (SCYa4), 
platelet-derived growth factor subunit B (PDGFb), poly(A)-specific ribonuclease (PARN), 
thrombospondin 1 (THBS1), tumor necrosis factor receptor superfamily member 1A 
(TNFRS1A), polycomb complex protein BMI-1, macrophage migration inhibitory factor 
(MIF), phosphodiesterase 4B (PDE4B), tyrosine-protein phosphatase non-receptor type 1 
(PTPN1), protein tyrosine phosphatase type IVA 2 (PTP4A2) and glutathione S-transferase 
P (GSTP1) – and progression to arthritis could be observed (see Table 2).
Subgroup analysis of patients with early progression to arthritis (that is, within 10 weeks 
after inclusion) showed significantly higher levels of mRNA expression of PARN and BMI1 
as compared to patients without progression to arthritis. The same results could be observed 
comparing levels of mRNA expression of PARN and BMI1 in early progressors to levels in 
all other included patients.
Table 1: Baseline characteristics of patients with arthralgia and positive anti-CCP or IgM-Rheumatoid Factor.
Total n = 137
Female sex, n (%) 104 (76 %)
Age, median (IQR) 47 yrs (39 – 55 yrs)
Follow-up, median (IQR) 21 months (15 – 31 months)
Progression to arthritis, n (%) 35 (26 %)
Time to arthritis, median (IQR) 11 months (3.7 – 18 months)
TJC 53, median (IQR) 0 (0 – 2)
RF positive, n (%) 82 (60 %)
Anti-CCP2 positive, n (%) 94 (69 %)
RF + anti-CCP positive, n (%) 39 (29 %)
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Table 2: levels of mRNA expression, circulating cytokines and circulating protein biomarkers in arthralgia patients 
with and without progression to arthritis
Arthritis
n= 35
No arthritis
n= 102
P-value
CBA Geometric mean (95% CI) Geometric mean (95% CI)
IL-12p70 7.08 (2.04 – 24.55) 1.91 (1.35 – 2.69) 0.07
TNF-α 2.95 (1.54 – 5.62) 1.45 (1.15 – 1.82) 0.07
IL-10 2.29 (1.26 – 4.17) 1.32 (1.15 – 1.51) 0.10
IL-6 2.69 (1.66 – 4.37) 1.58 (1.38 – 1.82) 0.05
IL-1β 10.0 (3.16 – 31.6) 5.50 (2.88 – 10.47) 0.39
IL-8 2.95 (1.70 – 5.13) 2.69 (2.04 – 3.55) 0.78
MLPA
IL-15 0.05 (0.04 – 0.05) 0.05 (0.04 – 0.05) 0.54
NF-κB1A 0.39 (0.35 – 0.44) 0.40 (0.38 – 0.42) 0.65
TNF 0.02 (0.02 – 0.02) 0.02 (0.02 – 0.02) 0.41
IL-1β 0.11 (0.10 – 0.13) 0.11 (0.10 – 0.12) 0.95
IL-1RN 0.35 (0.30 – 0.42) 0.35 (0.33 – 0.38) 0.99
IL-8 0.03 (0.03 – 0.04) 0.03 (0.03 – 0.04) 0.97
MYC 0.43 (0.38 – 0.49) 0.39 (0.36 – 0.42) 0.19
SCYa4 0.09 (0.08 – 0.10) 0.09 (0.08 – 0.10) 0.92
Serpin-B9 0.45 (0.39 – 0.51) 0.43 (0.41 – 0.45) 0.63
PDGF-β 0.03 (0.03 – 0.04 0.03 (0.03 – 0.03) 0.23
PARN 0.19 (0.18 – 0.20) 0.18 (0.17 – 0.19) 0.09
THBS1 0.05 (0.04 – 0.05) 0.04 (0.04 – 0.05) 0.16
LTA 0.05 (0.04 – 0.05) 0.05 (0.04 – 0.05) 0.09
CDKN1A 0.13 (0.11 – 0.16) 0.12 (0.11 – 0.13) 0.27
Tnfrsf1a 0.35 (0.32 – 0.39) 0.35 (0.34 – 0.36) 0.80
BMI1 0.11 (0.10 – 0.13) 0.10 (0.09 – 0.11) 0.08
MIF 0.26 (0.22 – 0.30) 0.25 (0.23 – 0.27) 0.73
PDE4b 0.34 (0.32 – 0.37) 0.34 (0.32 – 0.35) 0.84
PTPN1 0.07 (0.06 – 0.08) 0.07 (0.06 – 0.07) 0.53
PTP4A2 0.81 (0.76 – 0.87) 0.78 (0.74 – 0.81) 0.20
GSTP1 0.05 (0.04 – 0.05) 0.04 (0.03 – 0.05) 0.42
Biomarkers
Procalcitonin 0.04 (0.03 – 0.05) 0.04 (0.03 – 0.05) 0.69
hs-CRP (mg/L) 2.51 (1.72 – 3.66) 2.30 (1.82 – 2.90) 0.71
SPLA2 (ng/ml) 5.79 (4.75 – 7.07) 4.20 (3.20 – 5.53) 0.07
Subgroup analysis Early progressors
n = 18
No arthritis
n = 102
PARN 0.20 (0.18 – 0.22) 0.18 (0.17 – 0.19) 0.008
BMI1 0.13 (0.11 – 0.15) 0.10 (0.09 – 0.10) 0.02
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Biomarker levels
Mean sPLA2, hsCRP and PCT levels were not different between patients who developed 
arthritis and patients who did not; a trend towards higher sPLA2 levels in patients with 
arthritis could be observed (p = 0.07, see table 2). SPLA2 levels of arthralgia patients did 
not differ from SPLA2 levels of healthy controls (geometric mean (GM), 95%CI): 4.56, 
3.69-5.64 and 4.65, 3.84-5.64 respectively; p = 0.93), in contrast to the levels of RA patients 
(GM, 95%CI: 10.99, 6.93-17.42), that were significantly higher than both the levels of healthy 
controls and arthralgia patients (p <0.001). hsCRP levels of arthralgia patients on the other 
hand were higher than hsCRP levels of healthy controls (GM, 95%CI: 2.35, 1.93-2.86 and 
1.06, 0.72-1.55 respectively, p<0.001). hsCRP levels of RA patients were even higher (GM, 
95%CI: 7.58, 4.06-14.13; p <0.001).
discussion
This study of patients with an increased risk of developing RA was conducted to investigate 
whether differences in inflammatory patterns in those patients who developed arthritis 
could be observed before clinical signs of arthritis could be confirmed. We found no 
evidence of a more pronounced systemic acute phase response, higher cytokine levels or 
a higher expression of pro-inflammatory gene markers in patients who later progressed to 
arthritis than in those who did not, although a number of the biomarkers showed a trend 
towards higher levels in those that later developed arthritis. These data indicate that any 
possible local inflammatory processes in the joints of seropositive arthralgia patients do not 
result in a discernible systemic acute phase response activation.
These results are in contrast with our previous studies in which we reported elevation 
of CRP and SPLA2 levels in pre-clinical RA8, 9. A possible explanation for this discrepancy 
could be the difference in study design. In these previous studies multiple, longitudinally 
collected serum samples were analyzed and a slight but significant rise in CRP and SPLA2 
levels could be observed before RA onset, in contrast to stable levels in healthy controls. 
However, CRP and SPLA2 levels in preclinical RA were still within the normal range and 
therefore large numbers of samples are needed to detect such small changes. In this study 
a trend was observed toward higher levels of IL-12p70,TNF-α, IL-10, IL-6, PARN, LTA, 
BMI1,and SPLA2 in arthritis progressors; in early progressors higher levels of PARN and 
BMI-1 were observed. More significant differences might be observed when larger numbers 
of samples are analyzed. Also, in this study, hsCRP levels of arthralgia patients were higher 
than hsCRP levels of healthy controls, indicating that arthralgia patients have a slightly 
activated acute phase response on the group level.
Thus, although evidence exists for an induction of inflammation prior to the onset of 
RA, our data indicate that acute phase response markers such as CRP and SPLA2 are not 
useful in clinical practice as predictors of development of arthritis in individual high risk 
patients. This is in line with results from other studies in which hsCRP and SPLA2 in a 
single pre-RA serum sample were not increased in comparison to healthy controls10.
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In conclusion, although low grade inflammation is present before the onset of clinical 
arthritis in large cohorts and can be detected using consecutive measurements, a single 
measurement of acute phase reactants seems to be of limited value for prediction of devel-
opment of arthritis in individual patients.
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aBstract
objective
First, to determine whether procalcitonin (PCT) significantly adds diagnostic value in 
terms of sensitivity and specificity to a common set of markers of infection, including C-
reactive protein (CRP), at the Emergency Department. Second, to create a simple scoring 
rule implementing PCT values. Third, to determine and compare associations of CRP and 
PCT with clinical outcomes.
design
The additional diagnostic value of PCT was determined using multiple logistic regression 
analysis. A score was developed to help distinguish patients with a culture-proven bacterial 
infection from patients not needing antibiotic treatment using 16 potential clinical and 
laboratory variables. The prognostic value of CRP and PCT was determined using Spear-
man’s correlation and logistic regression.
setting
Emergency Department of a 310-bed teaching hospital.
Patients
Patients between 18 and 85 years old presenting with fever to the Emergency Department.
interventions
None.
measurements and main results
A total of 211 patients were studied (infection confirmed, n = 73; infection likely, n = 58; 
infection not excluded, n = 46; no infection, n = 34). CRP and chills were the strongest pre-
dictors for the diagnosis of bacterial infection. After addition of PCT to these parameters, 
model fit significantly improved (p = .003). The resulting scoring rule (score = 0.01 * CRP + 
2 * chills + 1 * PCT) was characterized by an AUC value of 0.83 (sensitivity 79%; specificity 
of 71%), which was more accurate than physician judgment or SIRS (systemic inflammatory 
response syndrome). PCT levels were significantly associated with admission to a special 
care unit, duration of intravenous antibiotic use, total duration of antibiotic treatment, and 
length of hospital stay, whereas CRP was related only to the latter two variables.
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conclusions
These data suggest that PCT may be a valuable addition to currently used markers of in-
fection for diagnosis of infection and prognosis in patients with fever at the Emergency 
Department.
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introduction
Fever is a common symptom at the Emergency Department and highly suggestive for 
microbial infection. Other clinical symptoms associated with infection are tachycardia, 
tachypnea, and abnormal leukocyte counts. Together these symptoms have been used to 
define the systemic inflammatory response syndrome (SIRS)1. Although the concept of 
SIRS is useful for detection of any inflammatory condition in patients, this syndrome is not 
specific enough to distinguish infectious from noninfectious causes of inflammation2, 3. In 
clinical practice, fever is still the most critical sign initiating a search for infection.
Currently, the differentiation between various causes of fever in clinical practice is based 
upon a combination of clinical parameters as well as laboratory values, including C-reactive 
protein (CRP) and leukocyte counts. In addition to these “conventional” markers, procal-
citonin (PCT) has been suggested as a novel infection biomarker4, 5. Several meta-analyses 
concluded that in critically ill patients, PCT is probably superior to CRP for diagnosing bac-
terial infection6-9. Nevertheless, the use of PCT in clinical practice is-at least in Emergency 
Department settings-still not established. An important reason is that despite this evidence, 
it remains unclear whether PCT adds significantly to the discriminative properties of the 
already used set of diagnostic markers, although this is an essential matter of concern in 
diagnostic research10.
This study aimed to determine the additional value of PCT as a biomarker in patients 
presenting with fever at the Emergency Department. We investigated the additional value 
of PCT to current markers in a multivariable logistic regression model and subsequently 
created a clinical scoring rule for diagnosis of bacterial infection. In addition, the role of 
PCT and CRP was further explored by studying associations with clinical outcomes.
methods
Patients
Between April 2004 and September 2006, patients presenting with fever admitted to the De-
partment of Internal Medicine of the Slotervaart Hospital in Amsterdam, The Netherlands, 
were included in the study. The study was approved by the Institutional Scientific and Ethics 
Committees. Eligible were nonpregnant adult patients, ages 18 to 85 yrs, presenting with 
fever. They were included in the study within 36 hrs after presentation. In close agreement 
with common clinical practice, fever was defined by a tympanic temperature >=38.0 ºC 
(Genius First Temp M3000A, Tyco Healthcare, Princeton, NJ) recorded either at admis-
sion or, when subfebrile at admission, between admission and inclusion. Written informed 
consent was obtained from all participating subjects.
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definitions
After completion of the study, the medical record of each included patient was reviewed 
by two blinded medical investigators, and in case of disagreement, reviewed by a third 
independent expert in infectious disease. Confirmed bacterial infection was defined by a 
positive culture at a likely focus (group 1). In the second group, with “possible infection,” 
infection was either likely (defined by positive imaging findings on a radiograph, computed 
tomography, or magnetic resonance imaging scan, such as an infiltrate or abscess confirmed 
by a radiologist and visual findings such as a localized warm, red and painful swelling or an 
abscess found by endoscopy) or could not be excluded. In the third, “noninfectious” group, 
bacterial infection was excluded because culture and imaging findings were negative and/
or an alternative diagnosis was confirmed. Chills were defined as a (sub) acute feeling of 
coldness together with shivering and feeling the need for a thick blanket. The judgment 
of the treating physician (who was not aware of PCT levels) about the likelihood of bacte-
rial infection was recorded at admission by personal inquiry by the investigator, or when 
this was not possible, by careful examination of the original patient’s medical records and 
medication use records.
measurements
Blood samples were obtained by venapuncture, collected on ice, and centrifuged within 15 
min. (2 x 3000 revolutions per minute at 5 ºC for 10 minutes). EDTA anticoagulated plasma 
was aliquoted and stored at -80 ºC. The blood was routinely screened for hematologic and 
biochemical variables. CRP was measured using an automated analyzer, Synchron LX20 
(Beckman Coulter, Fullerton, CA). PCT levels were measured by a chemiluminescence 
sandwich immunoassay (BRAHMS Aktiengesellschaft, Hennigsdorf, Germany) as previ-
ously described11.
The functional assay sensitivity is <0.007 ng/mL. The intra-assay coefficient of varia-
tion is <8% in samples containing 0.008-4 ng/mL. All samples were measured in a blinded 
fashion without knowledge of the clinical status of the patients.
data analysis
Group differences were calculated using Mann-Whitney U test for continuous variables and 
chi-square test for binominal variables. The association between the presence and absence 
of bacterial infection (group 1 and group 3, respectively) and each potential diagnostic de-
terminant (chosen based upon literature3, 12-21 was first quantified using univariate logistic 
regression analyses. Determinants with significant associations (p value <.20) were used to 
build a multivariable logistic regression model. Determinants from patient history, physical 
examination, and traditional laboratory markers of infection, including CRP, were included 
first, and the optimal model was determined. Then, PCT was added to this model. Differ-
ences in the discriminative value between the models with and without PCT were deter-
mined by comparing -2log likelihood ratios according to the chi-square goodness-of-fit test.
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For all variables included in the analysis, 95% or more of the data points were complete. 
Since multivariable analysis requires all data to be present in all subjects, we used regression 
imputation techniques to complete the missing values.
To adjust for the optimism in the regression coefficients, random bootstrapping techniques 
were applied using StatsDirect version 2.6.5 (StatsDirect Ltd, Altrincham, United King-
dom). Bootstrapping involves taking numerous samples with replacement from the study 
population sample. It is an internal validation technique (that is, it estimates the future per-
formance of the model without using new data)22. The data were bootstrapped 1000x and 
a final model was created. This model was transformed into a clinical scoring rule and the 
receiver operating curve area and other descriptive variables of this score were estimated. 
The derived scoring rule was then applied, for validation, to the likely infection group. 
Associations between PCT and CRP and relevant clinical parameters were determined by 
logistic regression analysis for binominal variables and Spearman’s ranked correlation test 
for continuous variables. Data are presented as medians with quartiles or as numbers with 
percentages; odds ratios (OR) with 95% confidence intervals (CI) and Spearman’s rho coef-
ficients are shown when appropriate. Data were analyzed using SPSS version 15.0.
results
Patients
A flow diagram of the 211 patients included is presented in Figure 1.
Presence of bacterial infection was confirmed for 73 patients (group 1), considered likely (n 
= 58) or could not be excluded (n = 46) for 104 other patients (possible infection, group 2), 
and was excluded for 34 patients (group 3). Patient characteristics are presented in Table 1.
diagnosis of infection
Univariate regression analysis was performed to identify markers of infection among 16 
clinical and laboratory candidate markers (Table 2). Groups 1 and 3 were compared. Sig-
nificant markers (p < .20) identified for the discrimination between confirmed infection 
and no infection were CRP, ESR, leukocyte count, (low) thrombocyte count, (low) albumin, 
tachypnea, and chills.
These variables were then included in a multivariable model (Table 2). Only levels of CRP 
and the presence of chills were significantly associated with confirmed infection. A new 
model was created using these variables. The area under the curve (AUC) of this model was 
0.79 (95% CI, 0.70 to 0.88). When PCT was added to this model, model fit was significantly 
improved (p = .003). The model with PCT had an AUC of 0.82 (95 CI, 0.74 to 0.90).
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We then adjusted the coefficients for overfitting by bootstrapping the data. Subsequently, 
the regression coefficients of the bootstrapped model were rounded to assign a score to each 
predictive variable. Thus, the following scoring rule was defined:
Score = 0.01 * Crp + 2 * Chills + 1 * Pct
Here, CRP is given in mg/l, PCT in ng/mL and chills is scored either 1 (present) or 0 (ab-
sent). Figure 2 shows the ROC curves of the several models. The scoring rule demonstrated 
an AUC of 0.83 (95% CI, 0.74 to 0.90). A model combining PCT and chills without CRP 
showed an AUC value of 0.76 (95% CI, 0.67 to 0.86). The optimal cut-off point (best di-
agnostic accuracy) of the scoring rule was 2.4, which showed a sensitivity of 79% and a 
specificity of 71%. This score corresponded with an 85% chance of having an infection.
Figure 1. Flow chart: Patient cohort of adults (n = 211) presenting with fever to the Emergency Department.
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Table 1. Patient characteristics of adults presenting with fever to the Emergency Department (n = 211)
 
 
All
N=211
n (%) /
median (IQR)
Bacterial 
Infection
N=73
n (%) /
median (IQR)
No bacterial 
infection
N=34
n (%) /
median (IQR)
P-value
Age, yrs 64 (46-74) 68 (52-74) 52 (43-67) 0.001
Sex, male n (%) 115 (55) 42 (58) 18 (53) NS
Underlying Morbidity, n (%)      
diabetes mellitus 37 (18) 13 (18) 5 (15) NS
Malignancy 17 (8) 4 (6) 7 (21) 0.017
HIV 12 (6) 4 (6) 3 (9) NS
COPD 53 (25) 21 (29) 5 (15) NS
congestive heart failure 20 (10) 10 (14) 1 (3) NS
Medication, n (%)      
Immunosuppressives 23 (11) 10 (14) 3 (9) NS
Antibiotics 48 (23) 17 (23) 6 (18) NS
Location, n (%)
Cardiovascular 1 (1) 0 (0) 1 (3) NS
Respiratory 101 (48) 29 (40) 8 (24) NS
Gastro-intestinal 34 (16) 13 (18) 11 (32) NS
Musculo-skeletal 3 (1) 1 (1) 2 (6) NS
Urogenital 32 (15) 22 (30) 1 (3) 0.002
Skin 12 (6) 6 (8) 1 (3) NS
lymph nodes 8 (4) 2 (3) 2 (6) NS
Other 4 (2) 0 (0) 3 (9) NS
Unknown 13 (6) 0 (0) 0 (0) NS
Duration of fever before inclusion, 
days 3 (2-6) 3 (2-7) 4 (2-9) NS
Duration of inclusion delay, days 1 (1-2) 1 (1-2) 1 (1-2) NS
Clinical symptoms, (%)      
Red painful swelling 32 (15) 10 (14) 8 (24) NS
Cough 101 (48) 35 (48) 9 (27) 0.036
Chills 94 (44) 36 (49) 10 (30) NS
Night sweating 48 (23) 17 (23) 9 (27) NS
Peaking temperatures 36 (17) 13 (18) 9 (27) NS
Nausea 64 (30) 25 (34) 12 (35) NS
Diarrhea 32 (15) 14 (19) 8 (24) NS
Dysuria 21 (10) 13 (18) 0 (0) 0.034
Clinical signs      
temperature, °C 38.9 (38.5-39.0) 39.0 (38.5-39.5) 38.9 (38.5-39.4) NS
tachypnea, n (%) 91 (43) 37 (51) 9 (27) 0.018
tachycardia, n (%) 83 (39) 27 (38) 12 (37) NS
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Various other cut-off levels are presented in Table 3, together with a comparison to alterna-
tive diagnostic approaches. The AUC of the scoring rule was superior to SIRS criteria and 
physician judgment of presence of bacterial infection. The rule was tested by applying it to 
the patient subgroup with likely infection determined by positive imaging findings, together 
with the no infection group. In these groups, the rule had an AUC of 0.80 (95% CI, 0.71 to 
0.89).
Prognosis
The prognostic value of the scoring rule determinants CRP and PCT is shown in Table 4. 
CRP levels were significantly associated with length of hospital stay and total duration of 
antibiotic treatment. PCT levels were also associated with these prognostic factors, but, 
in addition, were associated with duration of intravenously administered antibiotics and 
admission to a special care unit.
 
 
All
N=211
n (%) /
median (IQR)
Bacterial 
Infection
N=73
n (%) /
median (IQR)
No bacterial 
infection
N=34
n (%) /
median (IQR)
P-value
mean arterial blood pressure, 
mmHg 105 (95-120) 106 (91-121) 108 (97-119) NS
SIRS 166 (79) 63 (86) 22 (65) 0.010
Laboratory values
CRP, mg/l 139 (67-247) 179 (86-338) 73 (22-132) 0.000
BSE, mm/h 51 (31-84) 57 (37-87) 35 (20-75) 0.018
Leucocyte count, 109/l 11.0 (7.5-15.9) 11.1 (8.0-16.3) 8.8 (6.8-13.3) NS
Thrombocyte count, 109/l 230 (175-306) 220 (171-265) 246 (176-310) NS
AF, U/l 81 (63-108) 78 (68-109) 84 (60-113) NS
GGT, U/l 38 (23-64) 38 (23-78) 38 (20-64) NS
ASAT, U/l 22 (14-41) 26 (14-53) 21 (14-42) NS
ALAT, U,l 25 (16-45) 30 (18-56) 21 (14-41) NS
Albumin, g/l 29 (25-34) 27 (23-33) 33 (28-36) 0.001
PCT, ng/ml 0.27 (0.06-1.38) 0.67 (0.15-3.3) 0.15 (0.04-0.35) 0.000
Physician judgment infection 
present, n (%) 182 (86) 70 (96) 17 (50) 0.000
Mortality 5 (2) 1 (1) 0 (0) NS
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Figure 2. Receiver operating curve (ROC) curve. Graph plotting sensitivity against specificity of a novel scoring rule in 
adults presenting with fever to the Emergency Department. The scoring rule score was determined by 0.01 * [CRP] + 
1 * [PCT] + 2 * [chills]. CRP, C-reactive protein; PCT, procalcitonin.
Table 2. Univariate and multivariable analysis
Missing values, n (%) OR (CI) P-value
CRP 1 (0.5) 1.010 (1.005-1.015) 0.000
ESR 3 (1.4) 1.013 (1.000-1.026) 0.056
Leucocyte count 1 (0.5) 1.080 (0.996-1.172) 0.064
Thrombocyte count 8 (3.8) 0.997 (0.993-1.001) 0.132
AF 5 (2.4) 0.935 (0.995-1.004) 0.935
GGT 5 (2.4) 1.001 (0.997-1.005) 0.595
ASAT 1 (0.5) 1.000 (0.995-1.005) 0.943
ALAT 0 (0) 0.999 (0.996-1.001) 0.310
Albumin 7 (3.3) 0.881 (0.815-0.952) 0.001
Temperature 0 (0) 1.265 (0.692-2.314) 0.445
Tachypnea 0 (0) 2.855 (1.173-6.948) 0.021
Tachycardia 0 (0) 1.302 (0.575-2.949) 0.527
Pulse 0 (0) 1.014 (0.991-1.038) 0.229
Chills 0 (0) 2.335 (0.980-5.567) 0.056
Peaking temperature 0 (0) 0.602 (0.228-1.587) 0.305
Night sweating 0 (0) 0.843 (0.331-2.149) 0.721
PCT 2 (0.9) 2.576 (1.170-5.671) 0.019
Abbreviations: CRP= C-reactive protein, ESR= erythrocyte sedimentation rate, AF= alkaline phosphatase, GGT= 
gamma-glutamyl transferase, ASAT= aspartyl aminotransferase, ALAT= alanine transaminase, PCT= procalcitonin
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Table 3. Diagnostic accuracy-comparison to other diagnostic parameters of a novel scoring rule for the 
discrimination of bacterial infection in patients with fever at various cut-off levels (n = 211)
Diagnostic parameter AUC3 CI3 cut-off3 Sensitivity, %3 Specificity, %3
Decision rule1 0.83
 
 
0.74-0.90
 
 
2.4 0.79 0.71
0.7 0.95 0.32 
4.3 0.49 0.95 
CRP (mg/L) 0.76 0.67-0.85 133 0.62 0.79
9 0.99 0.18 
PCT (ng/mL) 0.73 0.63-0.82 0.7 0.52 0.91
0.5 0.53 0.85 
2.0 0.34 0.97 
10 0.16 1.00 
Chills 0.60 0.49-0.71 Yes/no 0.46 0.71
SIRS2 0.61 0.49-0.73 Yes/no 0.86 0.35
Physician judgment4 0.79 0.66-0.92 Yes/no 0.97 0.62
1Decision rule Score was determined by 0.01*[CRP] +1*[PCT] + 2*[chills]. CRP= C-reactive protein. PCT= procalcitonin.
2SIRS= Systemic Inflammatory Response Syndrome
3Area under the curves (AUC) with 95%-confidence intervals (CI) are presented from ROC curves summarizing 
performance of the decision rule score. Optimal cut-off values were defined as maximum sensitivity and specificity. 
Binominal variables were scored either present (yes) or not present (no).
4Judgment of treating physician of presence of bacterial infection as determined in the subgroups of proven 
bacterial infection versus infection excluded.
Table 4. Prognostic properties: Associations between plasma levels of C-reactive protein and procalcitonin and 
markers of prognosis in a patient cohort of adults presenting with fever to the Emergency Department (n = 211)
 
 
Median  
(IQR) /n (%)1
CRP PCT
rho/ OR1 CI1 p-value1 rho / OR1 CI1 p-value1
duration
hospital stay2, days 8 (5-13) 0.177 NA 0.011* 0.244 NA 0.000*
Duration
antibiotics2, days 10 (8-14) 0.318 NA 0.000* 0.308 NA 0.000*
duration
iv antibiotics2, days 6.5 (5-10) 0.113 NA 0.182 0.227 NA 0.007*
ICU/MC admission 13 (6%) 1.002 0.997-1.006 0.434 1.078 1.036-1.122 0.000*
30-day mortality 5 (2%) 0.996 0.987-1.005 0.389 1.030 0.968-1.096 0.346
1For continuous variables: median values are presented with interquartile ranges (IQR) and Spearman correlation 
coefficients (rho). For dichotomous variables: numbers of patients (n) are presented with odds ratio’s (OR) including 
the 95%-confidence interval (CI). A P<0.05 was considered statistically significant (*).NA= Not applicable. iv= 
intravenous.
2non-survivors excluded.
62
Procalcitonin for diagnosis of infection at the Emergency Department
discussion
This study first aimed to determine the additional value of PCT for use as a biomarker in 
patients presenting to the hospital with fever. Patients proven to have or not have a bacterial 
infection were compared with one another. The addition of PCT appeared to significantly 
improve a regression model using the level of CRP and the presence of chills, which were 
identified as the best discriminative markers among a set of commonly used markers for 
infection.
Second, by using these variables, we created a simple and easy to calculate scoring rule 
for clinical decision making. The rule showed an AUC of 0.83, which was superior to the 
use of SIRS or the clinical physician judgment. Third, PCT was associated more closely 
with clinical outcomes than CRP. Together the data demonstrate that PCT is a valuable 
addition to the currently applied set of biomarkers in patients presenting with fever to the 
Emergency Department.
In our study, at clinical cut-off levels, PCT tended to be more specific than CRP, whereas CRP 
was more sensitive. These different diagnostic properties may account for the additional 
diagnostic value of PCT in the scoring rule. One study compared sensitivity and specificity 
of CRP and PCT in patients presenting with fever at the Emergency Department before and 
showed more or less similar figures, but did not investigate the additional value of PCT to 
current markers23. The additional value of PCT was explored in two other studies with a dif-
ferent setup. One study presented a scoring rule for children with meningitis to distinguish 
between aseptic and bacterial meningitis24. PCT levels appeared to add diagnostic value 
to common clinical variables. Another study, using a different statistical approach via a 
classification and regression tree model, showed that PCT significantly added diagnostic 
value to currently determined variables for the identification of bloodstream infection in 
patients with fever25.
The scoring rule finally created showed comparable diagnostic properties in a validation 
cohort of patients with likely infection, which indicates that the rule may be applicable to 
other, similar cohorts of patients. The sensitivity and specificity of the scoring rule were 
79% and 71%, respectively. These figures were better than the diagnostic properties of PCT, 
CRP, or chills alone. Thus, the rule demonstrates a proof of principle that it is possible to 
combine various markers of infection in a way that is superior to the use of single markers 
only. It needs to be noted, however, that the negative predictive value of the rule (62%) was 
less than the negative predictive value of the physician judgment (85%); hence, the rule 
will not justify clinical decision making without consideration of the clinical condition of 
the patient and the (subjective) judgment of the treating physician. Furthermore, it must 
be emphasized that the rule must first be validated in a new cohort of patients (“external 
validation”), before it may be applicable in a clinical practice setting.
In addition to the diagnostic value of the markers, we investigated and compared prognostic 
values of PCT and CRP. The prognosis of a patient with fever is highly relevant for treat-
ment decisions such as the choice of ward for admission or the choice of antibiotics, their 
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route of administration, and the need for supportive measures. PCT levels in our study 
were predictive for multiple prognostic variables, including duration of stay in the hospital, 
duration of intravenously administered antibiotics, total duration of antibiotic treatment, 
and admission to a special care unit. In contrast, levels of CRP were associated only with 
duration of stay in the hospital and total duration of antibiotic treatment. This difference in 
prognostic properties has also been found by others and suggests that PCT is superior to 
CRP in terms of prognostic properties23, 26-29.
An ideal biomarker is not only useful for detection of the presence of illness, but also 
predicts absence of illness after recovery30. It has been demonstrated that the timing of 
discontinuation of antibiotic therapy in patients with pneumonia or sepsis could be safely 
guided by levels of PCT. In comparison to conventional, empirically-based antibiotic deci-
sion making, PCT-guided therapy greatly reduced numbers of antibiotic prescriptions and 
duration of antibiotic therapy31-35. Notably, the current scoring rule has not been designed 
for this purpose, but based upon the superior diagnostic properties of the rule as shown in 
this study in comparison with its single determinants, one could speculate that an approach 
that aims to combine both clinical and biological markers may also hold promise for refine-
ment of PCT-guided therapy algorithms.
The current study is an observational study. Observational studies are limited by their in-
ability to distinguish between primary and secondary effects and by difficulties to control 
for confounding factors36, 37. Because of definitions used in our study, the primary aim of 
the scoring rule was to identify the subset of patients with positive cultures as judged by 
the treating physician. Despite the confirmed presence of a bacterial infection, however, 
not all of these patients may ultimately require antibiotics, since a portion of patients may 
also recover without antibiotics. The reliability of the clinical-scoring rule may be further 
limited by the accumulation of error intervals of the single determinants, caused by techni-
cal limitations of the assays and a potentially subjective interpretation of the definition of 
chills. By reducing the amount of variables included in the rule to a minimum, we tried 
to minimize this error as much as possible. Furthermore, in the derivation cohort, only 
patients with proven infection were included to prevent mixing of results, but this selection 
may have caused a certain optimism in the AUC of the rule because of exclusion of patients 
with likely infection. Nevertheless, no differences were observed in patient characteristics 
in these groups. Taken together, the limitations of the rule emphasize the need for further 
validation of the rule in a new patient cohort.
conclusions
In conclusion, we showed that it was possible to create a simple, easy-to-calculate clinical 
scoring rule for the detection of infection in patients presenting with fever at the Emer-
gency Department which was diagnostically superior to physician judgment and SIRS. The 
biomarker PCT appeared to add significant diagnostic value in terms of sensitivity and 
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specificity to currently used markers of infection. In addition, PCT was a better prognostic 
marker than CRP. These data suggest that PCT may be a valuable addition to currently used 
markers of infection at the Emergency Department.
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aBstract
Purpose
Procalcitonin (PCT) has been shown to be of additional value in the work-up of a febrile pa-
tient. This study is the first to investigate the additional value of PCT in an Afro-Caribbean 
febrile population at the emergency department (ED) of a general hospital.
methods
Febrile patients were included at the ED. Prospective, blinded PCT-measurements were 
performed in patients with a microbiologically or serologically confirmed diagnosis or a 
strongly suspected diagnosis on clinical grounds.
results
PCT analysis was performed in 93 patients. PCT levels differentiated well between con-
firmed bacterial and confirmed viral infection (AUC of 0.82, sensitivity 85 %, specificity 
69 %, cut-off 0.24 ng/mL), between confirmed bacterial infection and non-infectious fever 
(AUC of 0.84, sensitivity 90 %, specificity 71 %, cut-off 0.21 ng/mL) and between all bacterial 
infections (confirmed and suspected) and non-infectious fever (AUC of 0.80, sensitivity 
85 %, specificity 71 %, cut-off 0.21 ng/mL). CRP levels were shown to be less accurate when 
comparing the same groups.
conclusion
This is the first study, showing that in a non-Caucasian febrile population at the ED, PCT is 
a more valuable marker of bacterial infection than CRP. These results may improve diagnos-
tics and eventually decrease antibiotic prescriptions in resource-limited settings.
keywords
Procalcitonin; infection; diagnostics; Afro-Caribbean; emergency department
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introduction
Infectious diseases are a major cause of morbidity and mortality worldwide, particularly in 
tropical regions1-3. Traditionally, fever has been associated with bacterial infection. How-
ever, in up to 50 % of febrile people, fever is caused by non-bacterial infection or other in-
flammatory conditions, such as malignancy or auto-immune disease4, 5. Because untreated 
bacterial infections may result in serious complications, the majority of patients with fever 
receive antibiotic treatment, leading to overprescription of antibiotics and contributing to 
the development of antimicrobial resistance, increasing costs and possible adverse effects6.
Neither clinical signs and symptoms, nor current biomarkers such as C-reactive protein 
(CRP) have, as a single marker, sufficient power to discriminate the etiology of fever7-9. 
Lately, procalcitonin (PCT) has been added to the diagnostic work-up of febrile patients. 
Levels of PCT, a prohormone of calcitonin normally produced by the thyroid in physiologi-
cal conditions, rise dramatically during bacterial infection, whereas low levels are detected 
during viral infections or non-infectious febrile conditions10-13. Both the diagnostic and 
prognostic properties of PCT have been shown to be superior to CRP in numerous stud-
ies11, 13-16.
PCT is (still) relatively expensive, which limits its application in resource-poor settings in 
tropical regions where infectious diseases are widely prevalent. Since antibiotic overuse also 
tends to be a large problem in these regions, improvement of the diagnostic work-up of 
fever is required here in particular. Unfortunately, research on PCT has almost exclusively 
focused on Caucasian populations in Northern countries. As such, it is difficult to apply 
these results directly to patients in tropical regions with different disease spectra and differ-
ent genetic backgrounds.
Therefore, this study aims to investigate the diagnostic and prognostic value of PCT and 
CRP in an Afro-Caribbean febrile population at the emergency department (ED) of a 
general hospital.
materials and methods
study design and patients
The study was conducted at the ED of the St. Elisabeth Hospital, Curaçao, Netherlands 
Antilles and was designed as a single center, observational cohort study. The study was 
approved by the local ethics committee for human studies. Written informed consent was 
obtained from all patients.
Between March 2008 and September 2009, all patients with fever (rectal T > 38.5 °C) 
were included within 24 hrs. after admission. Clinical data were registered, routine labora-
tory measurements were performed and cultures were taken. Patient follow-up was 60 days.
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Supplementary diagnostics were ordered by the attending physician. At the St. Elisabeth 
Hospital, bacterial diagnostics (i.e., cultures of body fluids and faeces) can be ordered rou-
tinely; viral diagnostics are limited to serology only. Regular imaging by means of X-ray, CT 
and MRI can be performed. No nuclear imaging can be performed.
definitions
Final diagnoses were made at discharge by an independent physician and again in retro-
spect by the main investigator, using all available data, including culture results, serology, 
radiology and pathology data. In case of a discrepancy between discharge diagnosis and the 
diagnosis in retrospect, an independent senior internist was asked to give a final clinical 
diagnosis.
When a causative bacterium or virus could be identified, either by culture or viral serol-
ogy, in concordance with patient history and clinical signs and symptoms, patients were 
assigned to the ‘confirmed bacterial’ or ‘confirmed viral’ groups. Confirmed parasites and 
fungi were classified as ‘confirmed infectious – other’.
When a specific micro-organism could not be identified, but clinical signs and symptoms 
were consistent with radiological or pathology findings – for instance, a clear history of 
fever, productive cough and dyspnea, abnormal pulmonary auscultation and an infiltrate on 
the X-thorax -, a clinical diagnosis was assigned and patients were assigned to the ‘suspected 
bacterial’ or ‘suspected viral’ group. Patients who were discharged without a clear – infec-
tious or non-infectious - diagnosis were included in the ‘rest’ group. When a non-infectious 
cause of the fever, without the presence of pathogenic micro-organisms, could be identified, 
patients were confined to the ‘non-infectious’ group.
measurements
Blood samples were obtained by venapuncture at inclusion. Samples were centrifuged 
within 15 minutes (2x 4000 rpm at 4 °C for ten minutes), aliquoted in 1 mL portions and 
stored at – 70 °C. The blood was routinely analyzed for hematological and biochemical 
variables, including CRP. Leukocyte count and differential was performed on the Siemens 
ADVIA 120 hematology analyzer, using light scatter, differential WBC lysis, and myeloper-
oxidase staining to determine WBC parameters. CRP measurements were performed on the 
Abbott c8000 chemistry analyzer using a latex-enhanced immunoturbidimetric method. 
Prospective, blinded PCT-measurements were performed by using a time-resolved ampli-
fied cryptate emission (TRACE) technology assay (Kryptor PCT, Brahms, Henningsdorf, 
Germany) in those patients assigned to the ‘confirmed bacterial’, ‘confirmed viral’, ‘con-
firmed infectious – other’ , ‘suspected bacterial’, ‘suspected viral’ and ‘non-infectious’ group.
All samples were measured in a blinded fashion without knowledge of the clinical status 
of the subjects.
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data analysis
Data were analyzed using SPSS version 17.0. Data are presented as numbers with percent-
ages or as medians with corresponding interquartile ranges. Associations between the 
presence and absence of bacterial infection and levels of PCT, CRP and leukocytes were 
quantified using logistic regression analysis and are expressed as odds ratios (OR) with 
95 % confidence intervals (CI) and p values. Areas under the curve (AUC) of the Receiver 
Operating Characteristics (ROC) curve were calculated. A p value < 0.05 was considered 
statistically significant.
results
Patients
During the study period, 462 patients with fever were identified. In 120 patients (94 % Afro-
Caribbean), a confirmed or strongly suspected diagnosis could be established. Due to logis-
tical problems – i.e. blood not processed or stored properly -, PCT could not be measured 
Table 1: Patient characteristics. Patient cohort of adults (n = 93) presenting with fever to the emergency department
All
n = 93
n (%) /
median (IQR)
Bacterial 
infection
n = 68
n (%) /
median (IQR)
No bacterial
infection
n = 25
n (%) /
median (IQR)
p-value
Age (yrs) 56 (36 – 72) 62 (43.5 – 73.5) 36 (28 – 53.8) < 0.001
Sex, male 55 (59.1) 40 (58.8) 16 (64.0) NS
Duration of fever before inclusion 
(days)
0 (0 – 1) 0 (0 – 1) 0 (0 – 1) NS
Clinical signs
Temperature (°C) 39.0 (38.8 – 39.8) 39.3 (38.9 – 39.8) 39.0 (38.7 – 39.5) NS
Tachypnea 20 (21.5) 16 (25.4) 2 (8.0) < 0.01
Tachycardia 57 (61.3) 43 (68.2) 14 (56.0) NS
Mean arterial blood pressure (mmHg) 110 (97 – 127) 111 (98 – 127) 107 (97 – 125) NS
Laboratory values
CRP (mg %) 12.1 (2.6 – 21.9) 15.3 (6.2 – 25.3) 2.8 (1.0 – 6.8) < 0.001
Leukocytes (giga/L) 11.4 (6.9 – 18.3) 13.1 (8.1 – 19.0) 9.0 (5.0 – 12.3) NS
PCT (ng/mL) 0.96 (0.21 – 5.16) 1.91 (0.32 – 8.73) 0.19 (0.12 – 0.66) < 0.001
Outcome
Mortality 12 (12.9) 11 (17.5) 1 (4.0) < 0.001
Hospitalization 66 (71.0) 49 (77.8) 18 (72.0) NS
Duration of hospital stay (days) 9 (4 - 15) 7 (1 – 13) 4 (0 – 7) 0.01
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in 27 of these patients. Analysis was performed in 93 patients. Patient characteristics are 
shown in table 1. A number of 67 patients (72.0 %) were hospitalized; from these patients, 
13 patients (14.0 %) died within the follow-up period of 60 days (median 9 days after inclu-
sions, IQR 2 -31 days) and 7 patients (7.5 %) were admitted to the Intensive Care Unit.
Final diagnoses are given in table 2. In 42 patients (45.2 %), bacterial infection was con-
firmed; in 26 patients (28.0 %), bacterial infection was suspected. In 4 patients (4.3 %), viral 
infection was confirmed; in 14 patients (15.1 %), viral infection was suspected. In 8 patients 
(8.6 %), a non-infectious cause of fever was identified (3 malignancy, 2 drug-induced fever, 
extra-uterine gravidity, sickle cell crisis, anaphylaxis).
markers of infection
Levels of PCT, CRP and leukocytes are shown in figure 1. Median PCT levels were 0.96 ng/
mL (IQR 0.19 – 5.22 ng/mL) in the overall cohort, 1.91 ng/mL (IQR 0.31 – 9.01 ng/mL) in 
patients with confirmed and suspected bacterial infection and 0.22 ng/mL (IQR 0.11 – 1.52 
Table 2: Final diagnosis of patients (n = 93) presenting with fever to the emergency department
Diagnosis n
Urinary tract infection 21
Bacterial pneumonia 20
Dengue fever 9
Skin infection 7
Bacterial sepsis, focus unknown 6
Diabetic foot 3
HIV 3
Bacterial meningitis 2
Central line sepsis 2
Viral gastro-enteritis 2
Pelvic inflammatory disease 2
Abscess 1
Viral pneumonia 1
Viral meningitis 1
Viral respiratory tract infection 1
Diverticulitis 1
Cholangitis 1
Bacterial gastro-enteritis 1
Influenza 1
Non-infectious fever 8
Chapter 6
75
ng/mL) in patients with confirmed and suspected viral infection; median CRP levels were 
12.1 mg % (IQR 2.4 – 22.0 mg %), 15.3 mg % (IQR 6.0 – 25.6 mg %) and 2.7 mg % (IQR 1.3 – 5.8 
mg %); median leukocyte levels were 11.4 giga/L (IQR 6.9 – 18.6 giga/L), 13.1 giga/L (IQR 
8.0 – 19.7 giga/L) and 6.6 giga/L (IQR 4.8 – 10.0 giga/L), in the same groups respectively.
diagnostic properties
PCT levels differentiated well between infectious and non-infectious fever (AUC of 0.76, 
sensitivity 78 %, specificity 71 %, cut-off 0.21 ng/mL; figure 2), between confirmed bacterial 
Figure 1: Levels of CRP, PCT and leukocytes in patients presenting with fever to the emergency department. Panel 
A shows levels of all patients together, panel B shows levels in patients with (confirmed or suspected) bacterial 
infection, panel C shows levels in patients with non-bacterial fever and panel D shows levels in patients with 
(confirmed or suspected) viral infection
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and confirmed viral infection (AUC of 0.82, sensitivity 85 %, specificity 69 %, cut-off 0.24 
ng/mL), between confirmed bacterial infection and non-infectious fever (AUC of 0.84, 
sensitivity 90 %, specificity 71 %, cut-off 0.21 ng/mL) and between all bacterial infections 
(confirmed and suspected) and non-infectious fever (AUC of 0.80, sensitivity 85 %, specific-
ity 71 %, cut-off 0.21 ng/mL). CRP levels were shown to be less accurate when comparing the 
same groups (AUC of 0.69, sensitivity 71 %, specificity 75 %, cut-off 8.3 mg %; AUC of 0.65, 
sensitivity 89 %, specificity 43 %, cut-off 8.5 mg %; AUC of 0.64, sensitivity 90 %, specificity 
43 %, cut-off 8.5 mg %, respectively).
Prognostic properties
A significant correlation between PCT levels and confirmed bacterial infection was observed 
(OR 1.088; 95 % CI 1.018 – 1.162; p = 0.013). A less strong, but still significant correlation 
between CRP levels and confirmed bacterial infection could be found (OR 1.046; 95 % CI 
1.004 – 1.090; p = 0.03). Leukocyte levels did not correlate with bacterial infection (OR 
1.043; 95 % CI 0.986 – 1.104; p = 0.14).
Figure 2: Receiver operating characteristic (ROC) curve, showing the diagnostic value of CRP, leukocytes and PCT for 
the differentiation between infectious fever and non-infectious fever. AUC PCT 0.76 (sensitivity 78% / specificity 71% 
at cut-off 0.21 ng/mL); CRP 0.59 (88% / 43% at 0.85 mg%); Leukocytes 0.41 (10% / 100 % at 28.0 giga/L), respectively
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discussion
In this study, we investigated the diagnostic and prognostic value of PCT and CRP in the 
diagnostic work-up of febrile patients at the ED of a general Caribbean hospital. Levels of 
PCT showed better diagnostic and prognostic properties than CRP. This is the first study 
to show that in a non-Caucasian febrile population at the emergency department, PCT is a 
more valuable marker of bacterial infection than CRP.
It has recently been shown in many studies that inter- and intra-racial genetic poly-
morphisms of inflammatory genes, including polymorphisms in the CRP-complex, are 
widespread and strongly influence the inflammatory response and the susceptibility to 
infectious diseases17, 18. Our study suggest that, regardless of multiple differences between 
genetic backgrounds and the different disease spectra, the positive results of PCT studies in 
Northern, Caucasian populations can likely be applied to an Afro-Caribbean population in 
a tropical region.
The relatively high costs of PCT measurements discourage application of PCT in resource-
poor settings. Furthermore, the PCT test is not readily available on most routine clinical 
chemistry analyzers. However, an improved diagnostic work-up of fever is likely to result in 
a decreased use of antibiotics, which will not only limit the costs of the drugs themselves, but 
also side-effect related costs. In the long term, increased costs due to antibiotic resistance 
are avoided. Indeed, studies have shown that the use of a PCT based algorithm reduced use 
of antibiotics in a general practice setting11. Moreover, recent studies have demonstrated 
that single PCT measurements may also be used to safely guide the duration of antibiotic 
therapy. In the landmark ProHosp trial, a large trial investigating 1359 patients with lower 
respiratory tract infections, a PCT based algorithm significantly reduced the duration of 
antibiotic therapy as well as frequencies of antibiotic side-effects and duration of stay in the 
hospital13. Although no cost-effectiveness analysis was carried out, costs were obviously 
reduced this way.
Some limitations concerning this study have to be noted. First, the study was an observa-
tional study, thus providing weaker empirical evidence than a randomized controlled study 
would provide. Also, in many febrile patients, no definite diagnosis could be established and 
PCT was not measured. This may have caused some selection bias; it could be suggested 
that patients with a clear diagnosis were more severely ill, resulting in more aggressive 
diagnostic procedures. This may explain the very high AUCs in this study, assuming that 
in more severely ill subjects, the acute phase reaction is activated more significantly in case 
of a bacterial infection. Nevertheless, the primary aim of our study was to compare PCT 
and CRP within the same study subjects. In addition, diagnostic possibilities in Curaçao 
are relatively limited. Viral diagnostics generally only consist of serology with emphasis 
on dengue fever; PCR is not used routinely. Therefore, our study may underestimate the 
presence of viral disease, which may have influenced overall outcomes.
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In conclusion, PCT is a valuable marker of bacterial infection in Afro-Caribbean febrile 
patients at the ED, with greater predictive value than CRP and other markers of infection. 
By implementing PCT as a routine marker in the work-up of febrile patients, diagnostic 
power will be improved. This may eventually lead to a reduction in antibiotic prescriptions, 
costs and adverse events.
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aBstract
aims and methods
To gain insight in the acute phase response and to investigate the value of procalcitonin 
(PCT) in children with suspected novel influenza A (H1N1) infection, 30 patients with 
suspected H1N1 infection were included.
results
Twenty-five patients (83.3 %) were diagnosed with a viral illness, including 9 patients with 
H1N1 infection. Median PCT levels, CRP levels and leukocyte counts in the subgroup with 
proven viral infections were 0.153 ng/mL with IQR 0.094–0.261 ng/mL; 19.0 mg/L with 
IQR 5.6–28.3 mg/L; and 13.1 giga/L with IQR 9.5–16.0 giga/L, respectively. PCT levels were 
below the lower cut-off value in 22 of 25 children (88%) with H1N1 infection and other viral 
diseases, whereas CRP levels and leukocyte counts were shown to exceed the lower cut-off 
value in 6 and 5 patients, respectively.
conclusion
Low PCT values seem to be of added value to support a diagnosis of viral infection during 
the diagnostic procedure in children with flu-like symptoms.
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introduction
In June 2009, the first patients with Novel Influenza A (H1N1) were diagnosed in The Neth-
erlands. Children under 5 years of age were particularly at risk for hospitalization, with a 
total of 574 hospitalized children under 5 years of age until December 2009, according to 
The National Institute for Public Health and the Environment.
Rapid diagnosis of children with flu-like symptoms is of great clinical importance, in par-
ticular for the guidance of clinical management. In case of a suspected influenza infection, 
there might be an indication to prescribe neuraminidase inhibitors, whereas in case of a sus-
pected bacterial infection, the patient should be treated with antibiotics. Both therapies are 
associated with possible side-effects, which urges the development of clinical and laboratory 
markers to distinguish between viral and/or bacterial infection1, 2. It has been shown that 
the discrimination of influenza from other viral and bacterial infections in children during 
an influenza epidemic, based on clinical signs and symptoms, is unreliable3. As testing for 
influenza by means of nucleic acid amplification techniques in practice takes one day or 
more, children with flu-like symptoms will often initially get treated with double-therapy 
until the final diagnosis is clear.
Earlier studies showed that the differentiated white blood cell count (WBC) and the C-
reactive protein (CRP) may exceed the upper limits of normal in children with adenovirus 
infection or influenza, sometimes mimicking findings as can be observed during bacterial 
infection4, 5. Discriminating between bacterial and viral infections, based on these param-
eters, might not be sufficiently adequate. In a number of pediatric studies, circulating levels 
of procalcitonin (PCT), the 116 amino acid pro-form of calcitonin, were mainly raised in the 
early stage of severe bacterial infection and only mildly raised in the absence of bacteria6-8. 
As a lower cut-off point for the exclusion of bacterial infection in children, values between 
0.53-0.9 ng/mL have been suggested9-11. We hypothesize that PCT might be a useful tool 
for the discrimination of children with bacterial infection from children with viral infection 
during an influenza pandemic.
To our knowledge, the acute phase response in children with H1N1 infection has not been 
described before. To be able to evaluate the value of PCT in children with suspected viral 
infection during the H1N1 pandemic, more information on the acute phase response is 
needed. This study was performed to gain insight into the acute phase response in children 
with suspected H1N1 infection. Furthermore, the value of PCT in children with suspected 
H1N1 infection was investigated.
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materials and methods
Patients
From October until December 2009, 30 consecutive children with suspected novel influenza 
A (H1N1) infection (i.e.: patients with fever (rectal temperature >38.2 °C or tympanic tem-
perature >38 °C) and at least two of the following complaints: cough, rhinorrhea, myalgia, 
sore throat, headache, chills, malaise) who underwent venapuncture for routine diagnostic 
purposes, were included at the freely accessible (i.e. no referral needed) influenza outpa-
tient clinic of the Slotervaart Hospital, Amsterdam, The Netherlands. As no extra blood for 
specific research purposes was needed and no additional patient discomfort was caused, 
informed consent was not deemed necessary.
diagnostic procedures
Standard blood tests included C-reactive protein (CRP) and differentiated white blood cell 
count (WBC). Quantitative PCT levels were measured using a specific immunometric assay 
(BRAHMS Ag, Hennigsdorf/Berlin, Germany) according to the protocol. From all patients 
a standard pharyngeal swab was obtained and, using primers as advised by the World 
Health Organization (WHO), real-time one-step polymerase-chain-reaction (RT-PCR) as-
says were used to detect the following pathogens: influenza A and subtype pH1N1, influenza 
B, rhinovirus, adenovirus, parainfluenza virus 1-4, enterovirus, human coronavirus, human 
metapneumovirus, respiratory syncytial virus, Legionella species, Mycoplasma pneumoniae 
and Chlamydia pneumoniae. Blood and sputum cultures, lumbar punctures and radiologic 
examinations were routinely ordered at the discretion of the treating physician.
statistical analysis
Values are presented as numbers with percentages or as medians with interquartile ranges 
(IQR). Correlations between CRP, leukocytes and PCT were assessed using Spearman’s cor-
relation test. Student’s t-test was used for inter-group comparison. A p-value of less than 
0.05 was considered significant. Statistical calculations were performed with SPSS software 
(version 17.0, SPSS Inc., Chicago, Illinois).
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results
Thirty consecutive patients were included. Patient characteristics are shown in Table 1.
Twenty-five patients (83.3%) were diagnosed with RT-PCR confirmed viral illness, three 
patients were diagnosed with a - clinically suspected - viral upper airway infection without 
positive RT-PCR result, one patient was diagnosed with a Mycoplasma pneumoniae infec-
tion and one patient was diagnosed with a non-confirmed bacterial pneumonia (double-
sided infiltrates on the thoracic X-ray and a good response to antibiotics; cultures negative). 
Overall, 9 cases of H1N1 (30%), 11 cases of rhinovirus (36.7%), 5 cases of respiratory syncytial 
virus (16.7%), 4 cases of adenovirus (13.3%) and one case of human metapneumovirus 
(3.3%) were diagnosed (Table 2). A total of 18 children (60%) were hospitalized. Patients 
with respiratory syncytial virus, rhinovirus and H1N1 were most frequently hospitalized 
(hospitalization rate 100%, 54.5% and 44.4%, respectively).
Median PCT value in the subgroup with confirmed viral infections was 0.153 ng/mL with 
IQR 0.094–0.261 ng/mL, median CRP value was 19.0 mg/L with IQR 5.6–28.3 mg/L and 
median leukocyte count was 13.1 giga/L with IQR 9.5–16.0 giga/L (Figure 1).
Table 1: Patient characteristics.
Characteristics Total n=30
Female sex, n (%) 19 (63.3)
Age (months), mean ± SD 24 ± 29.8
Body temperature (°C), mean ± SD 38.1 ± 1.01
Heart rate (bpm), mean ± SD 140 ± 24.5
Oxygen saturation (peripheral), mean ± SD 97.2 ± 3.2
Hospitalized, n (%) 18 (60)
Table 2: Detected viruses by means of RT-PCR in children with suspected Novel Influenza A (H1N1) (n=30) during the 
H1N1 pandemic.
Virus n %
Influenza A (H1N1) 9 30.0
Rhinovirus 11 36.7
Adenovirus 4 13.3
Respiratory syncytial virus 5 16.7
Human metapneumovirus 1 3.3
Sum of percentages for each virus exceeds the percentage of children diagnosed with a confirmed viral illness 
(83.3%) due to double infections.
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Combining this subgroup with the three cases with suspected, but non-confirmed viral in-
fection, did not significantly influence the results (median 0.155 ng/mL, IQR 0.09–0.262 ng/
mL; median 19.05 mg/L, IQR 5.53–28.53 mg/L; median 12.55 giga/L, IQR 9.13–15.88 giga/L for 
PCT, CRP and leukocyte count, respectively). The one case with non-confirmed bacterial 
pneumonia showed a marked acute phase response, with a PCT value of 32.17 ng/mL and 
a CRP value of 444.1 mg/L. The one case with metapneumovirus infection also exhibited 
elevated PCT and CRP (3.02 ng/mL and 42.3 mg/L), with normal leukocyte counts. The sen-
sitivity of PCT for viral infection was 88%, at a cut-off <0.71 ng/mL - the earlier described 
lower cut-off point in healthy neonates -10, whereas the sensitivity of CRP was 28% at a 
cut-off <10 mg/L and 76% at a cut-off <30 mg/L.
Subgroup analysis per virus of PCT, CRP and leukocyte counts did not show any significant 
difference (data not shown), although a trend towards significance could be observed in 
leukocyte counts, with lower counts in patients with H1N1 compared to the other viral 
infections (p=0.07).
In the overall cohort, a significant correlation between PCT and CRP (ρ 0.531, p=0.003), 
between CRP and leukocyte count (ρ 0.445, p=0.016), but not between PCT and leukocyte 
count (ρ 0.041, p=0.83) could be observed. Exclusion of the one case with suspected bac-
terial infection still resulted in a significant correlation between PCT and CRP (ρ 0.479, 
Figure 1: PCT levels (ng/mL), CRP levels (mg/mL) and leukocyte counts (giga/L) in patients (n=25) with a laboratory 
confirmed (RT-PCR) viral infection at presentation.
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p=0.010), between CRP and leukocyte count (ρ 0.383, p=0.044), and not between PCT and 
leukocyte count (ρ -0.065, p=0.74).
conclusion
Our study was aimed to characterize the acute phase response and to assess the value of 
PCT in children with suspected novel influenza A (H1N1) infection during the pandemic 
outbreak. Based on the results of this small cohort study, we can conclude that the acute 
phase response in children with H1N1 infection and other viral infections is mild, with low 
levels of CRP, PCT and leukocyte count. For CRP and leukocyte count, this is in conjuncture 
with earlier studies in children and adults4, 5, 12, 13.
We show that values of PCT are mostly below 0.71 ng/mL - the earlier described lower cut-
off point in healthy neonates -10 in children with viral infection of any cause. One patient 
with a human metapneumovirus infection had a PCT value of 3.02 ng/mL. The reason for 
this finding is unclear; one explanation might be that this patient was suffering from an 
undetected bacterial co-infection.
Levels of CRP were considerably low in the subgroup with viral infections and showed a 
significant correlation with PCT levels. However, in addition to the one patient with human 
metapneumovirus infection (CRP 42.3 mg/L), 5 other patients exhibited CRP values ≥30 
mg/L, whereas the generally accepted lower cut-off point is <10 mg/L14. In this cohort, in 5 
patients with a viral infection the leukocyte count was elevated (i.e. >17.5 giga/L). A correla-
tion with CRP, but not with PCT could be found.
In this cohort, PCT measurement in children with suspected H1N1 infection seems to be of 
added value during the diagnostic process. Low circulating levels of PCT appear to correlate 
with the presence of viral infection and/or the absence of bacterial infection. Although 
circulating levels of CRP show a correlation with PCT and are generally low in patients with 
viral infection, a considerable amount of patients had moderately elevated levels of CRP. 
The same holds true for leukocyte counts.
Given this findings, low PCT levels seem to be of added value to support a diagnosis of 
viral infection during the diagnostic procedure in children with flu-like symptoms.
This study has some limitations. Apart from the small cohort size, a major drawback lies 
in the fact that we almost uniformly included patients with viral infections. To be able to 
analyze the prognostic properties of PCT, CRP and leukocyte counts in differentiating 
between viral and bacterial infections, a group of children with bacterial infection from the 
same cohort is needed. During the study period, we were only able to include one patient 
with a - non-proven - bacterial infection. However, many earlier studies have shown that 
values of PCT during bacterial infection in children can be elevated6-8. Because of the small 
sample size, analysis of the acute phase response between patients infected with different 
viruses is difficult. A future study should be powered to discover possible differences in 
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levels of biomarkers between various viral infections. Another limitation is that diagnostic 
possibilities for bacterial infection in children are limited. To obtain culture materials may 
be difficult; moreover, a negative culture result does not exclude the presence of bacteria15. 
Although we confirmed the presence of virus in a large majority of our patients, a concomi-
tant bacterial infection may be present in some. However, all of these patients recovered 
without antibiotics, suggesting that this possible presence of bacterial co-infection is of little 
clinical importance.
The clinical presentation of children with flu-like symptoms is aspecific. There is a need 
for accurate discriminative diagnostic tools to guide therapeutic management. Besides 
optimalization of microbiological and molecular diagnostic tests, the role and the use of 
a selection of biomarkers may be helpful in the clinical setting. PCT in combination with 
clinical symptoms and routinely used markers may be of use in this context, directing the 
clinician in choosing antiviral or antimicrobial therapy, but also guiding the selection of 
those patients at risk of developing severe disease and need for intensive monitoring.
In children with flu-like symptoms, a rapid and adequate diagnosis is of great importance. 
Reliable biomarkers that are readily available may enhance and quicken the diagnostic 
process. Based on our findings, PCT may be of added value when the etiology of flu-like 
symptoms is unclear and the treating physician is uncertain whether to initiate or withhold 
antibiotics.
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aBstract
The long pentraxin PTX3 is a promising marker of disease severity in infection and inflam-
mation. Previous studies showed a strong correlation between mortality and high plasma 
levels of PTX3 in severely ill patients. In this study, we hypothesized that PTX3 may also 
be a predictive biomarker for disease severity in patients presenting with fever at an emer-
gency department. Therefore, levels of PTX3 were measured in 211 febrile patients at the 
emergency and the levels were linked to markers of disease severity including admittance 
to a special care unit, bloodstream infection and congestive heart failure. In comparison 
to median baseline levels of 2.30 ng/ml (interquartile range 1.66-3.67 ng/ml), levels of 
PTX3 were significantly elevated in patients admitted to the intensive-/medium care unit 
(median value 44.4 ng/ml, interquartile range 13.6-105.9 ng/ml) and in patients referred to 
the ward (median value 14.2 ng/ml, interquartile range 7.01-25.1 ng/ml); as such, PTX3 was 
a significant predictor of admission to the ICU/MC. In addition, PTX3 was a significant 
predictor of duration of hospital stay and a weak correlation was found with mortality, but 
this association was no longer significant after correction for acute congestive heart failure. 
Furthermore, this study showed that PTX3 was a significant predictor for bloodstream 
infection (AUC =0.71; 95% CI 0.62-0.81) and acute congestive heart failure. Taken together, 
these data show that PTX3 may be a useful marker for differentiation of patients with severe 
disease in patients presenting with fever to the emergency department.
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introduction
Fever is characteristic for many inflammatory conditions, yet it is particularly associated 
with bacterial infections. At the emergency department, a quick diagnosis is essential in 
patients with fever to define patients at risk for severe sepsis as soon as possible, as it has 
implications for treatment and prognosis; this has been referred to as ‘the golden hour of 
sepsis’1,  2. However, current diagnostic tools lack either speed, e.g. when taking bacterial 
cultures, or diagnostic value in terms of sensitivity and specificity3, 4. Plasma derived bio-
markers may be helpful to solve this issue. A promising biomarker for differentiation of 
patients with fever is the acute phase protein pentraxin 3 (PTX3)5.
The long pentraxin PTX3 belongs to an evolutionary conserved superfamily of pentraxins, 
which has been categorized into short and long pentraxins based on the structure of their 
subunits6-8. Other key members of this family include the short pentraxins C-reactive 
protein (CRP) and serum amyloid P component (SAP). Although the short and long pen-
traxins share common sequences, they are encoded by different genes and are differentially 
regulated5. The function of PTX3 is not completely clear, but involvement in inflammatory 
pathways is considered likely since mice lacking the gene encoding for PTX3 were shown to 
be highly susceptible for Aspergillus infections9.
Increased levels of PTX3 have been reported in multiple inflammatory conditions10-13. In 
critically ill patients with sepsis, highly increased levels were detected, which correlated 
with disease severity, ranging from the systemic inflammatory response syndrome (SIRS) to 
sepsis and septic shock14. Moreover, PTX3 was found to correlate significantly with mortal-
ity12,  14. Furthermore, PTX3 has also been linked to severity of disease in patients with 
cardiovascular disease including acute myocardial infarction, unstable angina pectoris and 
heart failure15-20.
Considering the potential of PTX3 as a biomarker in inflammatory disease, the marker is 
of interest to the relatively large group of patients presenting with fever to the emergency 
department. Therefore, we here aimed to determine levels of PTX3 in a cohort of 211 pa-
tients who presented to the emergency department with fever. In addition, the relationship 
was investigated between PTX3 and clinical markers linked to severity of disease, including 
admission to a special care unit, presence of bloodstream infection and congestive heart 
failure.
materials and methods
study design and definitions
The study was conducted at the emergency department of the Slotervaart hospital, Am-
sterdam, The Netherlands, between April 2004 and October 2006; the study protocol has 
been described in detail elsewhere21. The study was approved by the institutional scientific 
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and ethics committee of the Slotervaart hospital, Amsterdam, the Netherlands. Written 
informed consent was obtained from all subjects. Adult patients, 18-85 years old, present-
ing with fever to the emergency department were included. Fever was defined as an ear 
temperature of 38.0°C or higher. For diagnosis of bacteraemia, a total of 3 blood cultures 
were taken. Other, local bacterial and viral cultures were taken from the suspected focus of 
infection as judged by the treating physician. Mortality and admission to the intensive care 
unit or medium care (ICU/MC) were determined for a period of 30 days after admission. 
Bacteraemia was defined as a positive blood culture with a likely pathogen, considering 
the underlying disease, within 7 days of admission. According to the results, pathogens 
were classified into gram-negative or gram-positive organisms. Congestive heart failure was 
diagnosed by the treating physician based upon symptoms of dyspnea, radiologic findings 
and response to diuretic therapy. A medical history of heart failure in patient records was 
considered positive only in combination with current use of heart failure medication.
laboratory methods
Blood samples were obtained by venapuncture at inclusion and follow-up. The samples 
were centrifuged within 15 minutes (2x 3000 rpm at 5 °C for ten minutes), aliquoted and 
stored at -80 °C. Plasma levels of PTX3 were measured using a sandwich enzyme-linked 
immunosorbent assay as previously described22. Plasma PTX3 levels are expressed as ng/
ml. Other laboratory investigations were routinely performed by the clinical laboratory and 
the department of microbiology of the Slotervaart Hospital, Amsterdam, The Netherlands.
statistical analysis
Data analyses were performed using SPSS version 15.0. Group differences were calculated 
using Mann-Whitney U test. To determine correlations between plasma levels of PTX3 and 
relevant clinical parameters, logistic regression analysis was performed for binominal vari-
ables and Spearman’s ranked correlation test for continuous variables. Data are presented 
as medians with corresponding interquartile ranges (IQR) or as numbers with percentages; 
odds ratios (OR) with 95 % confidence intervals (CI) and Spearman’s rho coefficients are 
shown when appropriate. A p value <0.05 was considered significant.
results
Patients
In total, 211 patients were included. From these, a number of 15 patients was admitted to the 
intensive care unit (n =10) or medium care unit (n =5); these patients are further referred to 
as the ICU/MC group versus the ‘ward’ group (n =194). Patient characteristics are shown in 
table 1. Median age was 67 years (IQR 61-72 years) and 63 (IQR 46-74 years) in the ICU/MC- 
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and ward group, respectively. Five patients died. At a one-month follow-up visit, samples 
were collected from 55 people who returned after full recovery of their illness.
PtX3 levels and disease severity
Levels of PTX3 are shown in figure 1. At baseline, median PTX3 levels were 2.30 ng/ml (IQR 
1.66-3.67 ng/ml). The levels were increased in ward patients (14.2 ng/ml; IQR 7.01-25.1 ng/
ml; p =0.0009), whereas highly elevated levels were observed in patients admitted to ICU/
MC (44.4 ng/ml; IQR 13.6-105.9 ng/ml; p <0.0001).
Table 1. Patient characteristics
 
 
Non-ICU/MCU
N=194
n (%) /
median (IQR)
ICU/MCU admission
N=15
n (%) /
median (IQR)
Age, years 62 (45-74) 69 (62-77)
Sex, male n (%) 106 (54%) 9 (60%)
Underlying morbidity
malignancy, n (%) 17 (9%) 0 (0%)
HIV, n (%) 9 (5%) 1 (7%)
diabetes mellitus, n (%) 32 (16%) 5 (33%)
Location
cardiovascular, n (%) 1 (1%) 0 (0%)
respiratory, n (%) 94 (48%) 7 (47%)
gastro-intestinal, n (%) 31 (16%) 3 (20%)
Musculo-skeletal, n (%) 3 (2%) 0 (0%)
urogenital, n (%) 27 (14%) 4 (27%)
skin, n (%) 12 (6%) 0 (0%)
other, n (%) 12 (6%) 0 (0%)
unknown, n (%) 16 (8%) 1 (7%)
SIRS, n (%) 151 (77%) 15 (100%)
Sepsis, n (%) 53 (27%) 10 (67%)
Positive culture, n (%) 64 (33%) 10 (67%)
Positive blood culture, n (%) 31 (48%) 4 (40%)
Gram-positive, n (%) 29 (45%) 5 (50%)
History of congestive heart failure, n (%) 19 (10%) 7 (47%)
Acute congestive heart failure, n (%) 13 (7%) 7 (47%)
C-reactive protein, ng/ml 139 (68-246) 169 (66-284)
Hospital stay, days 7 (4-12) 22 (18-32)
30-day mortality, n (%) 2 (1%) 3 (20%)
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Using logistic regression analysis, PTX3 was a significant predictor of ICU/MC referral (OR 
=1.014; 95% CI 1.006- 1.021; p <0.0001). After adjustment of this association for conges-
tive heart failure, the OR was 1.013 (95% CI 1.005-1.020; p =0.001). PTX3 levels showed a 
Figure 1: Levels of PTX3. PTX3 was measured in 211 patients presenting with fever to the emergency department. 
Patients were admitted either to the ward or to the intensive care- or medium care unit (ICU/MC) and baseline 
samples were collected at a 1-month follow-up visit.
Figure 2: ROC curve for prediction of bacteraemia by PTX3. Levels of PTX3 and blood culture results were determined 
in 211 patients presenting with fever to the emergency department.
Chapter 8
97
weak association with mortality (OR 1.010; 95% CI 1.002-1.019; p =0.018). After adjustment 
for congestive heart failure, the association was no longer significant (p =0.120). The total 
duration of hospital stay correlated with PTX3 values at admission (Spearman’s rho 0.191; 
p =0.006). Levels of PTX3 correlated with levels of CRP (Spearman’s rho 0.355; p <0.0001).
Bloodstream infection
A significant correlation between PTX3 levels and presence of bloodstream infection was 
observed (OR 1.012; 95% CI 1.005-1.020; p =0.002). The Receiver Operating Characteristic 
curve is presented in figure 2. The area under the curve was 0.71 (95% CI 0.62-0.81).
At a previously set ‘normal’ cut-off value of PTX3 of 2.0 ng/ml, our data showed a sensitivity 
of 100% with a specificity of 2%. The optimum cut-off value was 16.1 ng/ml, which showed 
a sensitivity and specificity for prediction of bloodstream infection of 76% and 61%, respec-
tively. Other cut-off points are presented in table 2. The levels of PTX3 were not differentially 
associated with infection by either gram-negative or gram-positive organisms.
congestive heart failure
PTX3 was associated with acute congestive heart failure (OR 1.008; 95% CI 1.002-1.015; p 
=0.016). In addition, PTX3 levels at admission were related to a positive medical history of 
heart failure (OR 1.007; 95% CI 1.000-1.013; p =0.047); however, after adjustment for acute 
congestive heart failure this association was not significant. Baseline levels of PTX3 did not 
correlate with a medical history of heart failure.
discussion
In this study, we investigated the potential use of the long pentraxin PTX3 as a biomarker in 
patients presenting with fever to the emergency department. At admission, levels of PTX3 
in febrile patients were significantly elevated in comparison to samples collected after full 
recovery at a one-month follow-up visit. Moreover, in patients admitted to the ICU/MC, the 
Table 2: Cut-off values of PTX3 for prediction of bloodstream infection in patients presenting with fever to the 
emergency department.
Cut-off value
(ng/ml)
Sensitivity Specificity Positive predictive 
value
Negative predictive value
2.00 100% 2% 16% 100%
7.96 90% 29% 20% 94%
16.1 76% 61% 27% 93%
43.8 36% 90% 40% 88%
100 15% 98% 56% 86%
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levels of PTX3 were higher in comparison to levels of patients referred to the ward; as such, 
PTX3 was shown to be a significant predictor of admission to the ICU/MC. In addition, 
PTX3 was a significant predictor of duration of hospital stay and a weak correlation was 
found with mortality, though this association was no longer significant after correction for 
acute congestive heart failure. Furthermore, this study showed for the first time that PTX3 
was a significant predictor for bloodstream infection and that, in agreement with data from 
others16, 17, the levels correlated with acute congestive heart failure. Taken together, these 
data show that PTX3 may be a useful marker for differentiation of patients with severe 
disease in patients presenting with fever to the emergency department.
Fever is a presentation symptom which is more than any other symptom suggestive for 
microbial infection and sepsis. In recent years, it has become increasingly clear that in pa-
tients with sepsis, early recognition of severe disease is of major importance to therapy and 
prognosis, as it was demonstrated that early, aggressive treatment may reduce mortality and 
that the efficacy of many sepsis intervention strategies appears to depend on the prognosis 
of the patient23,  24. Within this context, there is a need for biomarkers to predict severe 
disease such as PTX3. The findings in our study, which showed that PTX3 correlated with 
ICU/MC admission and duration of hospital stay, are consistent with findings in patients 
with SIRS, sepsis or septic shock at the ICU and in patients who suffered from severe lepto-
spirosis or dengue virus infections12, 14. Of note, associations with disease severity were also 
reported recently in other conditions such as renal failure, acute myocardial infarction or 
psoriasis10, 15, 19, 20, 25. As such, PTX3 is a stable, promising predictor of disease severity in 
different patient populations with inflammatory disease.
The plasma levels of PTX3 that were found in this study in patients with fever were 14.2 
ng/ml in the ward group and 44.4 ng/ml in the ICU/MC patients. These levels are higher 
than a previously set ‘normal’ value of 2.0 ng/ml15, though, like in the current study, also 
slightly higher baseline levels have been reported12. The levels found in the current study 
are relatively high as compared to levels in moderately ill patients showing median values 
of 2.84 ng/ml and 6.20 ng/ml in patients with psoriasis and unstable angina pectoris, re-
spectively10, 18. However, comparable levels of 28.0 ng/ml were found in patients with SIRS, 
whereas in septic shock much higher levels were observed with a median of 251 ng/ml14. 
These results indicate that not only within studies, but also between studies, PTX3 levels 
associate with the severity of the immunological stimulus.
Bloodstream infection is associated with a higher mortality than localized infection; thus, it 
must be regarded as a marker of disease severity3, 26, 27. Studies showed that other biomark-
ers such as procalcitonin, CRP or coagulation markers were able to predict bloodstream 
infection28-30. The data from the current study show that PTX3 may be an additional marker 
for bloodstream infection. The optimum cut-off value in our study was 16.1 ng/ml, which 
showed a sensitivity of 76% and specificity of 61%. Though, like most current biomarkers in 
this setting, these figures are not sufficient for diagnosis and clinical decision making based 
upon the value of PTX3 alone, these predictive properties of PTX3 are of interest to current, 
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promising efforts aiming to combine various biomarkers into one single, optimal predictive 
model21, 30, 31.
The association found in the current study between acute congestive heart failure and 
PTX3 is consistent with earlier research showing higher levels of PTX3 in patients suffering 
from myocardial infarction, unstable angina pectoris or heart failure15-19. The underlying 
mechanism may be related to activation of inflammatory pathways induced by myocardial 
stress32. Also coagulation pathways may be involved, as was suggested after finding en-
hanced expression of tissue factor, which is a major initiator of the coagulation cascade, in 
monocytes and endothelial cells stimulated by PTX333, 34.
The precise pathophysiological role of PTX3 remains to be elucidated. Like other pentrax-
ins, PTX3 is not only an acute phase protein, with elevated levels as a result of inflamma-
tion, but also acts as a component of innate immunity5,  8. A protective role of PTX3 was 
demonstrated in PTX3 knock-out mice with fungal infections, displaying a beneficial effect 
on immunity and clinical outcome9. PTX3 appears to be stored in specific granules in neu-
trophils and can be secreted to neutrophil extracellular taps in response to immunological 
stimuli35. Further mechanisms include regulation of complement activation via binding of 
PTX3 to complement factors36 and a role in the regulation the recognition of apoptotic cells 
by inflammatory cells37.
Investigators have suggested previously that PTX3 may be selectively induced by various 
pathogens13. It was demonstrated that PTX3 binds to Pseudomonas aeruginosa, Salmonella 
typhimurium, and Paracoccidioides brasiliensis, but not to Escherichia coli, Burkholderia 
cepacia, and Listeria monocytogenes9. In fungi, PTX3 was bound selectively to Aspergillus 
fumigatus, Aspergillus flavus and Aspergillus niger, but not to Candida albicans9. Because of 
these results and because differential associations were found between the short pentraxin 
CRP and gram-negative bacteraemia38, we tested this hypothesis for the difference between 
gram-negative and gram-positive organisms and PTX3; yet we found no association.
Observational studies are limited by their inability to distinguish between primary and sec-
ondary effects and by difficulties to control for confounding factors39, 40. Nevertheless, they 
have often proven useful to find patterns of associations helping to elucidate mechanisms 
of clinical disease. With these limitations in mind, the current study shows that in patients 
presenting with fever to the emergency department, levels of PTX3 were elevated and corre-
lated with disease severity parameters including admission a special care unit, bloodstream 
infection and congestive heart failure. As such, alone or in combination with other markers, 
PTX3 may be a valuable biomarker for disease severity at the emergency department.
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Fever as a symptom of disease remains a challenge for clinicians. Fever, often associated with bacterial infection, can be the result of a variety of pathological conditions. Even 
though relatively new diagnostic tools, such as polymerase chain reaction (PCR), have been 
successfully introduced in daily clinical practice, a fast and reliable diagnosis of diseases 
causing fever is still difficult to obtain. Commonly used tests for this purpose have low 
sensitivity and specificity; as a result, patients are frequently treated solely based on circum-
stantial evidence. It is important to improve diagnostics in the field of fever. Not only for 
patients - who will receive the appropriate treatment faster and will suffer less unnecessary 
side effects of drugs that have been wrongfully prescribed -, but also for society in general, 
aiding the combat against antibiotic resistance and reducing health care costs.
In this thesis, we aimed to study biomarkers in inflammation and infection, with a special 
focus on the distinction between infectious and non-infectious fever. Epidemiological 
knowledge is the first step in the process of finding better biomarkers for diagnosing febrile 
patients. Therefore, after a general introduction in chapter 1, in chapter 2 the epidemiol-
ogy of patients presenting with fever at an Emergency Department (ED) in Amsterdam, 
the Netherlands and Curaçao, Netherlands Antilles is presented. We show that both in the 
Netherlands and in Curaçao, mortality in these patient groups is considerably high (4.2 and 
7.9 %, respectively) and most patients suffer from bacterial infections. However, approxi-
mately 1 out of 20 febrile patients at the ED is eventually diagnosed with a non-infectious 
cause of fever, with malignancy as most notable underlying cause. Although no data on 
incidence of non-infectious fever at the ED have been published before, the incidence of 
infectious fever we find is comparable to that found by others; therefore, our findings can be 
extrapolated to other hospitals worldwide. 
Proving the absence of bacterial infection may be worth as much as demonstrating the 
presence of bacterial infection and may in some situations be easier and enough to guide 
therapy. In chapter 3, we therefore review the literature investigating the diagnostic value 
of biomarkers during episodes of non-infectious fever. Among many possible markers, for 
now procalcitonin (PCT) seems to be the most sensitive and specific laboratory marker for 
this purpose, particularly in autoimmune, autoinflammatory and malignant diseases.
In Part II, we describe our studies in different patient cohorts with focus on biomarkers, 
suitable for discriminating between – bacterial - infection and non-infectious inflammation. 
In chapter 4, we focus on the predictive value of biomarkers in patients with arthralgia, 
with some of these patients progressing to rheumatoid arthritis, a non-infectious, inflam-
matory disease with a marked acute phase response. We observed a trend towards higher 
levels of several markers of the acute phase response in those patients who progressed to 
rheumatoid arthritis; these higher levels may be of use for research purposes, but do not 
possess enough diagnostic power to have clinical consequences on the individual level. 
In chapter 5, 6 and 7 we compare sensitivity and specificity of different commonly used 
and experimental biomarkers in different febrile patient groups. Chapter 5 describes the 
development of a clinical decision rule for the prediction of bacterial infection in febrile 
patients at an emergency department in Amsterdam. We show that adding PCT to a 
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model including a clinical variable (cold chills) and a commonly used laboratory marker 
(C-reactive protein (CRP)) leads to superior predictive power. In Chapter 6 we demonstrate 
for the first time that PCT is a valuable biomarker of bacterial infection in a febrile Afro-
Caribbean population. Chapter 7 focuses on febrile children during the 2009 influenza A 
(H1N1) pandemic. In a small cohort study, we show that regular diagnostic tests such as 
white blood cell count and CRP are unreliable for the diagnosis of viral disease and that 
PCT may be of added value when the treating physician is uncertain whether to withhold 
antibiotics.
Not every bacterial infection requires treatment with antibiotics. Knowing which pa-
tient needs to be treated without any further delay and which patient can be safely observed 
without treatment, would be very helpful in daily practice. In chapter 8 we investigate the 
correlation of several biomarkers with severity of disease. We conclude that the long pen-
traxin-3 (PTX-3), a relatively new and unknown marker of the acute phase response, may 
serve as a good indicator of severity of disease and mortality in patients with fever at the 
emergency department.
discussion and recommendations for future research
Epidemiology of infectious diseases is continuously changing with place and time. Patho-
gens are evolving and (re-)emerging, climate change brings new diseases and eliminates 
others, medicines cure patients but may create new diseases. New diagnostic tools give rise 
to the discovery of completely new and unexpected pathogens. It is important to systemati-
cally investigate and document the pathogens involved in febrile disease in different regions 
worldwide. With better knowledge of which pathogens to expect while examining a febrile 
patient, the pre-test chance of a positive finding with an appropriately chosen test will be 
higher, enabling physicians to diagnose patients more accurately. Systematic in- and out-
hospital surveillance will help to detect possible infectious threats more effectively. With 
a better understanding of the epidemiology of disease, better preventive measures can be 
taken. 
For optimal diagnostics in febrile disease, one should be able to prove either the presence 
of a pathogen (at the same time excluding other pathogens) or non-infectious disease with 
certainty. Given the enormous amount of pathogens and non-infectious febrile conditions, 
this seems far out of reach. On the other hand, the introduction of PCR as a diagnostic tool 
into clinical practice already has led to much more possibilities for achieving this objec-
tive. Further research should focus on the impact of PCR and other molecular techniques 
that give us the opportunity to demonstrate or exclude many pathogens with one fast and 
reliable test. Until better direct diagnostic tests have been validated, the results for the bio-
markers as presented in this thesis are of much added value in the diagnostic work-up of a 
febrile patient. For now, PCT seems the most reliable and effective of the newly introduced 
markers. With a vast amount of clinical data from retrospective and prospective studies, use 
of PCT now becomes more and more accepted in daily clinical practice. 
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Despite many clinical studies with promising results, the (patho-)physiological role of PCT 
remains unclear. Whereas CRP has been well-characterized in many studies - both from the 
point of view of production, which almost uniformly takes place in the liver after stimu-
lation by IL-6, as from its function, the binding to phosphocholine expressed on certain 
microbes and on necrotic or apoptotic cells, thus activating the complement system via 
C1q and enabling opsonization1 – to date, it is not yet elucidated what the source of ‘inflam-
matory PCT’ is. Under physiological circumstances, PCT is produced in the C-cells of the 
thyroid gland and practically all is converted into calcitonin, resulting in very low levels of 
circulating PCT. Whereas thyroid C-cells react to several stimuli, such as hypercalcemia, 
glucocorticoids, glucagon and β-adrenergic stimulation, by releasing more PCT, no link 
between ‘inflammatory PCT’ and these stimuli can be shown.2 A strong link between bacte-
rial endotoxins, as well as TNF, and elevated PCT levels has been established.3 It has been 
hypothesized that PCT is involved in modulation of NO synthesis, and, as such, should be 
classified as a pro-inflammatory cytokine. Also, PCT has been proposed to have an analge-
sic effect, with an association between lower levels of nocireceptors and higher PCT levels.4 
Lastly, it was shown that exogenous administration of PCT in septic animals led to an 
increase in mortality; as such, PCT may not only be an indicator of severity of disease, but 
may also increase mortality via an unknown pathway.5 Given the fact that during bacterial 
infection the human body spends its energy on the production of large quantities of PCT, 
one would assume that there must be a pathophysiological role for PCT. Future research 
is needed to further clarify this. Despite the uncertainty about the source of PCT and its 
function, it is the first biomarker since the introduction of CRP that literally found its way 
from bench to bedside and provides a welcome addition to the current diagnostic panel.
However, a well-designed randomized prospective cohort study, evaluating PCT as a guide 
for antibiotic therapy in febrile patients visiting the emergency department is still lacking. 
We conducted a pilot-study at the Slotervaart Hospital in Amsterdam, the Netherlands, 
showing that use of PCT leads to a reduction of antibiotic use and is safe, with no difference 
in mortality or length of hospital stay between a PCT-guided antibiotic therapy group and 
the control group. In this study, all patients at the Emergency Department with fever, defined 
as a temperature > 38.2 ˚C, were included and randomized to the PCT-guided antibiotic 
therapy-arm or the standard-of-care arm. Routine clinical work-up was performed in all 
patients, including routine laboratory analysis and necessary supplementary diagnostics as 
judged by the attending physician. After finishing the work-up, the attending physician was 
required to give a provisional diagnosis, discerning between bacterial- and non-bacterial 
disease; furthermore, the physician was asked to state whether antibiotics were deemed 
necessary. After this, for patients in the PCT-guided arm, the PCT-value was visible for the 
treating physician. Based on pre-defined cut-off values, an advise on antibiotics was given 
(PCT < 0.5 ng/mL; no antibiotics advised – PCT > 0.5 ng/mL; antibiotics advised). The 
treating physician could ignore the PCT-based advise at all times, but was in that case asked 
for a motivation.
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One hundred and eight patients were included. PCT was a better predictor of bacterial 
infection than other laboratory measurements, including CRP. In the PCT-guided group, 
fewer antibiotics were prescribed as compared to the standard-of-care group. There was no 
difference in length of hospital stay or mortality between groups. 
From this small pilot study, we can conclude that PCT-guided antibiotic therapy seems 
useful and safe in patients with undifferentiated fever at the Emergency Department. We are 
currently starting up a large trial to further confirm these findings.
As mentioned above, biomarkers are able to guide us through the work-up of febrile patients, 
providing us with important information that adds up to other clinical findings, resulting 
in a treatment plan with or without antibiotics. However, after the very start of infection 
or inflammation, it takes substantial time for biomarkers to be produced. Moreover, the 
measurement of circulating biomarkers is a ‘downstream’-measurement, and as infection 
and inflammation share many common immunological pathways, important differentiating 
information will not be available. Ideally, one should be able to measure biomarker produc-
tion at the source, that is, at the site of RNA-production. 
In clinical practice, the introduction of new and very sensitive molecular techniques such 
as PCR has contributed to easier diagnosis of viral disease.6 To date, however, growth of 
bacteria remains the gold standard for the confirmation of bacterial infections. As cultiva-
tion of bacteria is not straight-forward, with many species growing slowly and requiring 
special media, it is often difficult or even impossible to confirm bacterial etiology, resulting 
in overuse of antibiotics and uncertainty about definite diagnosis. To overcome the problem 
of cultivation, the host response to a certain pathogen could be used as a diagnostic tool. 
It has been extensively shown that host gene signatures differ with different pathogens. 
Specific pattern-recognition receptors are expressed on leukocytes and can be measured 
in vivo.7,8  It has not only been shown that comparison of global gene expression profiles 
reveals specific signatures for bacteria; also, gene expression profiling has been shown to be 
a valuable tool to distinguish auto-immune disease from viral disease, and to distinguish 
one virus from another.8,9 
Micro-arrays, such as MLPA as described in chapter 4, measure the differences in expres-
sion of thousands of genes during physiological and pathological states. By measuring gene 
expression in a parallel way, micro-array based techniques allow for different molecular 
pathways in the cell to be studied and insight is provided in the dynamics of physiological 
and pathological processes. Furthermore, subtle differences in gene expression can be de-
termined, as micro-arrays are very sensitive. Micro-arrays can be used both for genotyping 
and gene expression measurements. Genotyping can be used to analyze the genomic DNA 
content of a pathogen; gene expression can be measured in either pathogen or host, thus 
enabling investigation of host-pathogen interactions. 
Micro-arrays can thus be used as valuable tools for diagnosis of infection by means 
of organism detection or discovery of novel pathogens, can be used for epidemiological 
investigation and can give insight in virulence of pathogens. Furthermore, the host response 
can be measured dynamically and susceptibility to certain pathogens can be evaluated.10, 11
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One of the clinical shortcomings of micro-arrays is the enormous amount of informa-
tion they provide. In a hospital setting, most of this information is too detailed and as such 
irrelevant. For patient care, presence or absence of specified pathogens should be confirmed 
in a fast and reliable way. It has been shown that a relatively small selection of gene expres-
sion in the host is sufficient to answer these basic questions, by measuring pathogen-specific 
gene expression signatures or patterns.8 These patterns do not only indicate the presence 
of different types of bacterial or viral infections; by comparing over- and under-expression 
of RNA with the mean expression in healthy controls, a relative ‘distance to health’ can be 
estimated, thus indicating severity of disease.12 
If the use of micro-arrays as diagnostics in febrile disease becomes more practically 
feasible, diagnostic procedures will be faster and more reliable. The dynamics of the acute 
phase response during different pathological conditions will be unraveled from a ‘host per-
spective’, not only resulting in more reliable diagnostics, but potentially also in new targets 
for therapy. As the use of micro-arrays is becoming easier and cheaper, micro-arrays will 
find their way to hospital use and will probably replace biomarker testing in the upcoming 
decades. 
Further biomarker studies in febrile patient populations should not only prospectively 
evaluate if PCT can indeed be used as a diagnostic tool in a larger population with undiffer-
entiated fever, but also if a PCT-guided therapy is safe and cost-effective. Another potential 
strength of PCT, which has not been evaluated in this thesis but has been shown mostly in 
Intensive Care studies13, 14, is its ability to guide termination of antibiotics after treatment 
has been initiated. Despite earlier suggestions that the average duration of treatment with 
antibiotics might be too long15, clinicians still tend to treat infections for at least seven days. 
Declining PCT values may be used as a guide for shorter treatment. Again, a well-designed 
prospective non-ICU study needs to be undertaken.
In our opinion, gene profiling studies will be the focus of biomarker research in the next 
decade. It will be very interesting to perform sequential gene expression during infection 
and inflammation, mapping the dynamics of gene pathways in health and disease. With 
better applied bioinformatics, future studies will enable the streamlining of the massive 
amount of information gene profiling techniques provide, and hopefully result in new sets 
of biomarkers - from bench to bedside.
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Koorts blijft voor artsen een lastig te interpreteren symptoom van ziekte. Bij koorts wordt vaak gedacht aan bacteriële infectie, maar koorts kan ontstaan door een veel-
heid aan ziektebeelden. Ondanks de recente klinische introductie van nieuwe diagnostische 
hulpmiddelen, zoals de polymerase chain reaction (PCR), is het nog altijd moeilijk om een 
snelle en betrouwbare diagnose te stellen bij patiënten met koorts. De doorgaans gebruikte 
diagnostische onderzoeken hebben een lage sensitiviteit en specificiteit; dientengevolge 
worden patiënten vaak slechts behandeld op basis van indirecte aanwijzingen. Het is belang-
rijk om de diagnostiek in het ‘koortsveld’ te verbeteren; niet alleen voor patiënten, die met 
snellere en betere diagnostiek eerder de juiste therapie zullen krijgen en daardoor minder 
last zullen hebben van onnodige bijwerkingen door onterecht voorgeschreven medicatie, 
maar ook voor de maatschappij, om antibiotica-resistentie terug te dringen en kosten van 
de gezondheidszorg te reduceren.
In dit proefschrift hebben wij biomarkers bij ontsteking en infectie onderzocht, waarbij 
vooral gekeken is naar het onderscheid tussen infectieuze en niet-infectieuze koorts. De 
eerste stap op weg naar betere biomarkers voor diagnostiek bij koortspatiënten bestaat uit 
gedegen kennis van epidemiologie van koortsende ziektes. Om die reden wordt - na een 
algemene introductie in hoofdstuk 1 – in hoofdstuk 2 de epidemiologie van patiënten die 
zich met koorts op de Spoedeisende Eerste Hulp (SEH) in Amsterdam en Curaçao pre-
senteren, beschreven. We laten zien dat in Nederland en op Curaçao mortaliteit in deze 
patiëntengroep aanzienlijk is (respectievelijk 4.2 % en 7.9 %) en dat de meerderheid van 
patiënten een bacteriële infectie heeft. Ongeveer 1 op de 20 patiënten met koorts op de SEH 
blijkt echter niet-infectieuze koorts te hebben, met maligniteiten als meest voorkomende 
onderliggende ziekte. Incidentie-data van niet-infectieuze koorts op de SEH zijn niet eerder 
gepubliceerd; aangezien de door ons gevonden incidentie van infectieuze koorts vergelijk-
baar is met de incidentie zoals door anderen gevonden, lijkt extrapolatie van onze data naar 
andere ziekenhuizen wereldwijd gerechtvaardigd.
Het bewijzen van afwezigheid van bacteriële infectie, in plaats van het aantonen van de 
áánwezigheid ervan, kan in klinische situaties evenveel waard zijn, is soms eenvoudiger en 
kan voldoende zijn om therapeutische beslissingen te sturen. In hoofdstuk 3 presenteren 
we een overzicht van de literatuur waarin de diagnostische waarde van biomarkers tijdens 
episodes van niet-infectieuze koorts is onderzocht. Op dit moment lijkt procalcitonine 
(PCT), naast andere mogelijke markers, de meest geschikte laboratoriumtest voor het on-
derscheid tussen infectieuze en niet-infectieuze koorts, met name bij auto-immuun, auto-
inflammatoire en maligne ziektes.
In Deel II ligt de nadruk op biomarkers en hun rol in het onderscheid tussen (bacteriële) 
infecties en niet-infectieuze ontsteking. We lichten in hoofdstuk 4 de voorspellende waarde 
van biomarkers toe bij patiënten met arthralgie, waarbij sommige patiënten reumatoïde 
arthritis ontwikkelen, een niet-infectieuze ontstekingsziekte met een uitgesproken acute 
fase-reactie. We observeerden een trend richting hogere waardes van verschillende markers 
van de acute fase-reactie in die patiënten die uiteindelijk reumatoïde arthritis ontwikkelden; 
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deze hogere waardes kunnen van waarde zijn voor verder onderzoek op groepsniveau, 
maar de verschillen zijn te klein om klinische consequenties te hebben voor de individuele 
patiënt.
In hoofdstuk 5, 6 en 7 vergelijken wij de sensitiviteit en specificiteit van verscheidene 
veelgebruikte en experimentele biomarkers in verschillende patiëntengroepen met koorts. 
Hoofdstuk 5 beschrijft de ontwikkeling van een klinische beslisregel die de aanwezigheid 
van bacteriële infectie voorspelt bij patiënten met koorts op de SEH in Amsterdam. We 
laten zien dat een model bestaand uit PCT, een klinische variabele (koude rillingen) en 
een veelgebruikte laboratoriumtest (C-reactive protein (CRP)) de grootste voorspellende 
waarde voor dit doel geeft. In hoofdstuk 6 tonen wij voor het eerst aan dat PCT een waar-
devolle biomarker is voor bacteriële infectie in een Afro-Caribische populatie. Hoofdstuk 7 
beschrijft een cohort van kinderen met koorts tijdens de 2009 influenza A (H1N1) pande-
mie. In een kleine cohortstudie tonen wij aan dat reguliere laboratoriumdiagnostiek naar 
virusinfectie met behulp van CRP en hoeveelheid witte bloedcellen onbetrouwbaar is en 
dat PCT bij deze kinderen van toegevoegde waarde kan zijn als de behandelend arts twijfelt 
over het al dan niet geven van antibiotica.
Niet iedere bacteriële infectie hoeft antibiotisch te worden behandeld. Voor de dagelijkse 
praktijk is het belangrijk te weten welke patiënt met spoed moet worden behandeld met 
antibiotica en welke patiënt veilig geobserveerd kan worden zonder behandeling. In hoofd-
stuk 8 onderzoeken wij de correlatie van verscheidene biomarkers met ernst van ziekte. We 
concluderen dat het long pentraxin-3 (PTX-3) – een relatief nieuwe en onbekende marker 
voor acute fase-reactie – een goede voorspeller van ernst van ziekte en van mortaliteit kan 
zijn bij mensen met koorts op de SEH.
Discussie en aanbevelingen voor verder onderzoek
Epidemiologie van infectieziekten is locatie- en tijdsgebonden. Pathogenen evolueren, 
klimaatverandering staat aan de wieg van nieuwe ziektes en elimineert andere; medicijnen 
genezen patiënten, maar kunnen op hun beurt weer nieuwe ziektes induceren. Nieuwe diag-
nostische hulpmiddelen dragen bij aan de ontdekking van volledig nieuwe en onvermoede 
pathogenen. Het is en blijft belangrijk om de pathogenen, betrokken bij het ontstaan van 
koortsende ziektes in de gehele wereld, systematisch in kaart te brengen. Door meer kennis 
kan een behandelend arts beter anticiperen op de aanwezigheid van bepaalde pathogenen 
bij een patiënt met koorts, waardoor de pre-test kans op een positieve bevinding bij een juist 
gekozen test toeneemt en de diagnostiek nauwkeuriger wordt. Systematische surveillance 
binnen en buiten het ziekenhuis zal bijdragen tot eerdere detectie van mogelijke infectieuze 
dreiging. Door grotere kennis van verspreiding van ziekte kunnen betere preventieve maat-
regelen worden genomen.
Voor optimale diagnostiek van koortsende ziektes zou men enerzijds de aanwezigheid van 
een pathogeen met zekerheid moeten kunnen aantonen en tegelijkertijd andere pathogenen 
of niet-infectieuze koortsende ziektes uit moeten kunnen sluiten. Gezien de overweldigende 
hoeveelheid pathogenen en niet-infectieuze koortsende ziektebeelden, lijkt dit te hoog 
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gegrepen. Daar staat tegenover dat het aantonen van verwekkers, sinds de klinische intro-
ductie van PCR- en andere moleculaire technieken, makkelijker is geworden. Toekomstig 
onderzoek moet laten zien of deze technieken ons in staat stellen om pathogenen met een 
simpele en robuuste test aan te tonen of uit te sluiten. Totdat betere diagnostische testen zijn 
gevalideerd, is het ‘indirecte bewijs’ dat verkregen wordt door gebruik van biomarkers bij 
het aanvullend onderzoek van patiënten met koorts van grote waarde. Op dit moment lijkt 
PCT de meest betrouwbare en effectieve nieuwe marker. Mede dankzij een grote hoeveel-
heid klinische data, verkregen uit retrospectieve en prospectieve, goed-opgezette en grote 
studies, valt wordt de PCT-test steeds belangrijker in de dagelijkse klinische praktijk. 
Ondanks een veelheid aan klinische studies met veelbelovende resultaten, blijft de (patho-) 
fysiologische rol van PCT onopgehelderd. Waar de fysiologie van CRP duidelijk omschre-
ven is – met enerzijds de productie, die vrijwel volledig plaatsvindt in de lever na stimulatie 
door IL-6, en anderzijds de functie, het binden van fosfocholine dat tot expressie wordt 
gebracht door bepaalde micro-organismen en door necrotische of apoptotische cellen, 
waardoor het complementsysteem via C1q wordt geactiveerd en opsonisatie mogelijk wordt1 
– is tot op heden niet duidelijk waar het ‘ontstekings-PCT’ geproduceerd wordt. Onder fy-
siologische omstandigheden wordt PCT geproduceerd door de C-cellen van de schildklier 
en wordt vrijwel al het PCT direct omgezet in calcitonine, waardoor het circulerend PCT 
erg laag is. Ondanks het feit dat de C-cellen van de schildklier na verscheidene stimuli, 
zoals hypercalciëmie, glucocorticoïden, glucagon en β-adrenerge prikkels, reageren met het 
afgeven van meer PCT, kan er geen relatie tussen deze stimuli en het ‘ontstekings-PCT’ 
worden gevonden.2 Er is sprake van een duidelijke relatie tussen bacteriële endotoxines en 
TNF met hoge waardes van circulerend PCT.3 Er wordt gesteld dat PCT betrokken is bij de 
modulatie van NO-synthese en op die manier als pro-inflammatoir cytokine geclassificeerd 
zou moeten worden. Tevens zou PCT mogelijk een pijnstillend effect hebben, waarbij een 
associatie tussen de aanwezigheid van minder noci-receptoren bij hogere PCT-waardes is 
aangetoond.4 Als laatste is verder gebleken dat de experimentele toediening van exogeen 
PCT aan septische dieren een hogere mortaliteit gaf; op die manier zou PCT niet alleen 
een indicator zijn voor ernst van ziekte, maar mogelijk ook direct de mortaliteit kunnen 
verhogen via een vooralsnog onbekend mechanisme.5 Vanwege het feit dat het menselijk 
lichaam tijdens een bacteriële infectie aanzienlijke hoeveelheden energie spendeert aan de 
productie van PCT, lijkt het aannemelijk dat PCT een pathofysiologische rol moet spelen. 
Verder onderzoek is nodig om dit te verduidelijken. Ondanks de onduidelijkheid over 
de herkomst van PCT tijdens infectie en de functie, is PCT de eerste biomarker sinds de 
introductie van CRP die zijn weg van het lab naar het ziekenhuisbed heeft weten te vinden, 
en vormt het een welkome aanvulling op de reeds bestaande diagnostische markers. 
Een goed-opgezette, gerandomiseerde, prospectieve cohortstudie die PCT gebruikt als 
leidraad voor antibiotische therapie bij patiënten met koorts op de SEH, ontbreekt nog. 
Wij hebben een pilot-study uitgevoerd in het Slotervaartziekenhuis te Amsterdam, 
waarin we aantonen dat het gebruik van PCT leidt tot minder antibioticagebruik en veilig 
is. In deze studie werden alle SEH-patiënten met koorts, gedefinieerd als een temperatuur 
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> 38.2 ˚C, geïncludeerd en gerandomiseerd, waarna behandeling ofwel plaats vond bin-
nen de ‘PCT-geleide antibiotische therapie-arm’, ofwel binnen de standard-of-care arm. De 
gebruikelijke klinische diagnostiek werd bij alle patiënten uitgevoerd, inclusief routine-
bloedonderzoek en al het verdere aanvullend onderzoek dat volgens de behandelend arts 
geïndiceerd was. Na afronden van de diagnostiek werd de behandelend arts gevraagd om 
een werkdiagnose, met een onderscheid tussen bacteriële- en niet-bacteriële ziektes; daar-
naast werd de behandelend arts gevraagd een uitspraak te doen over de noodzaak van het 
geven van antibiotica. Hierna werd de PCT-uitslag van patiënten binnen de PCT-geleide 
arm vrijgegeven. Gebaseerd op tevoren vastgestelde afkapwaarden werd op basis van de 
uitslag een antibiotica-advies gegeven (PCT < 0.5 ng/mL; geen antibiotica geadviseerd – 
PCT > 0.5 ng/mL; antibiotica geadviseerd). De behandelend arts kon dit advies te allen tijde 
negeren; wel werd dan om een motivatie gevraagd. 
108 Patiënten werden geïncludeerd. PCT was een betere voorspeller van bacteriële 
infectie dan andere laboratoriumbepalingen, inclusief CRP. In de PCT-geleide groep wer-
den minder antibiotica voorgeschreven in vergelijking met de controlegroep. Er was geen 
verschil in duur van ziekenhuisopname of in mortaliteit tussen de groepen. 
Uit deze kleine pilot-study kunnen we concluderen dat PCT-geleide antibiotische thera-
pie zinvol en veilig lijkt te zijn bij patiënten met ongedifferentieerde koorts op de SEH. Op 
dit moment starten wij een grote studie om dit nader te bekijken.
Zoals hierboven beschreven, vormen biomarkers een goede aanvulling op de diagnostiek bij 
koortspatiënten; mede aan de hand van biomarkers wordt in de praktijk een behandelplan 
met of zonder antibiotica opgesteld. Echter, tussen het begin van infectie of inflammatie en 
de productie van biomarkers gaat een aanzienlijke hoeveelheid tijd voorbij. Het meten van 
biomarkers is een ‘downstream’-meting, en aangezien infectie en inflammatie veel overlap 
kennen in de immunologische ‘pathways’, gaat stroomafwaarts potentieel onderscheidende 
informatie verloren. In de ideale situatie zou biomarkerproductie gemeten moeten worden 
bij de bron, i.e. op de plek van RNA-productie. 
In de klinische praktijk heeft de introductie van nieuwe en erg gevoelige moleculaire 
technieken als PCR geleid tot eenvoudigere diagnostiek naar virusziektes.6 Tot nu toe blijft 
echter het kweken van bacteriën de gouden standaard voor het bevestigen van bacteri-
ele infectie. Aangezien het kweken van bacteriën niet altijd even eenvoudig is, met soms 
langzame groei en de noodzaak tot kweken op speciale media, is het in de praktijk veelal 
moeilijk of zelfs onmogelijk om bacteriële etiologie te bewijzen. Hierdoor wordt vaak on-
nodig antibiotisch behandeld en blijft er onzekerheid over definitieve diagnoses bestaan. 
Om dit probleem op te lossen, zou de reactie van de gastheer tegen een bepaald pathogeen 
als diagnosticum kunnen worden gebruikt. Het is veelvuldig aangetoond dat er bij infectie 
met specifieke pathogenen kenmerkende gen-expressiepatronen meetbaar zijn bij de 
gastheer. Specifieke ‘pattern-recognition receptors’ worden op witte bloedcellen tot expressie 
gebracht en kunnen in vivo worden gemeten.7, 8. Niet alleen is bewezen dat door vergelijking 
van gen-expressieprofielen gedifferentieerd kan worden tussen verschillende bacteriën; 
gen-expressieprofielen kunnen tevens gebruikt worden als middel om auto-immuunziektes 
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van virusinfecties te onderscheiden, en om verschillende virussen onderling te kunnen 
onderscheiden.8, 9
Micro-arrays - zoals de MLPA, beschreven in hoofdstuk 4 – meten patronen van ver-
schillen in genexpressie van duizenden genen tegelijk in fysiologische en pathologische om-
standigheden. Door genexpressie parallel te meten, kunnen met behulp van micro-arrays 
verschillende intracellulaire cascades worden bestudeerd en kan meer inzicht worden 
verkregen in de dynamiek van fysiologische en pathologische processen. Aangezien micro-
arrays erg sensitief zijn, kunnen subtiele verschillen in genexpressie worden vastgesteld. 
Micro-arrays kunnen worden gebruikt voor genotypering en voor het meten van genex-
pressie. Genotypering kan worden gebruikt om het genomisch DNA van een pathogeen te 
analyseren; genexpressie kan in het pathogeen of in de gastheer worden gemeten, waardoor 
het mogelijk is om interacties tussen pathogeen en gastheer te onderzoeken.
Micro-arrays kunnen waardevolle middelen zijn bij de diagnostiek van infectie door 
de detectie van (nieuwe) pathogenen, kunnen gebruikt worden voor epidemiologisch on-
derzoek en kunnen meer inzicht geven in de virulentie van pathogenen. Daarnaast kan de 
reactie van de gastheer op pathogenen dynamisch gemeten worden en kan de gevoeligheid 
van de gastheer voor bepaalde pathogenen in kaart worden gebracht.10, 11
Eén van de klinische gebreken van micro-arrays is de enorme hoeveelheid informatie 
die ze genereren. In het ziekenhuis is het grootste deel van deze informatie te gedetailleerd 
en daarom irrelevant. Voor goede patiëntenzorg gaat het erom de aan- of afwezigheid van 
specifieke pathogenen op een snelle en betrouwbare manier aan te tonen. Eerder onderzoek 
heeft laten zien dat een relatief kleine selectie van genexpressie in de gastheer afdoende 
is om deze basale vragen te beantwoorden door het meten van pathogeen-specifieke 
‘genexpressie-handtekeningen’ of patronen.8 Deze patronen tonen niet alleen de aanwezig-
heid aan van verschillende soorten bacteriële of virale infecties; door het vergelijken van 
over- en onderexpressie van RNA met de gemiddelde expressie in gezonde controles, kan 
een relatieve ‘afstand tot gezondheid’ worden geschat, waardoor ernst van de ziekte gekwan-
tificeerd kan worden.12
Als het gebruik van micro-arrays in de klinische praktijk beschikbaar komt, zullen 
diagnostische procedures sneller en betrouwbaarder worden. De dynamiek van de acuut-
fase reactie tijdens verschillende pathologische situaties zal ontrafeld worden vanuit een 
‘gastheerperspectief ’, wat niet alleen zal resulteren in betrouwbaarder diagnostiek, maar 
mogelijk ook in nieuwe aangrijpingspunten voor therapie. Nu micro-arrays goedkoper 
en eenvoudiger in gebruik worden, zullen zij hun weg naar het ziekenhuis vinden en de 
komende decennia hoogstwaarschijnlijk het reguliere testen van biomarkers vervangen.
Verdere biomarkerstudies in patiëntenpopulaties met koorts moeten niet alleen prospectief 
evalueren of PCT daadwerkelijk gebruikt kan worden als diagnostische test in een grotere 
populatie met ongedifferentieerde koorts; tevens zal moeten worden onderzocht of PCT 
veilig en kosten-effectief is. Een andere mogelijke kracht van PCT, die niet is geëvalueerd 
in dit proefschrift maar vooral in eerdere Intensive Care-studies is aangetoond13, 14, is de 
mogelijkheid om PCT-geleid antibiotica te staken nadat therapie begonnen is. Ondanks 
eerdere suggesties dat de gemiddelde antibiotische behandeling bij infecties mogelijk te lang 
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is15, neigen clinici er nog altijd naar infectie minimaal zeven dagen te behandelen. Dalende 
PCT-waardes zouden kunnen worden gebruikt als leidraad voor kortere behandeling. Ook 
hier is een goed-vormgegeven prospectieve niet-IC-studie nodig.
Naar onze mening zal het focus van biomarkerstudies het komende decennium liggen op 
genexpressiestudies. Het zal erg interessant zijn om sequentieel genexpressie tijdens infectie 
en inflammatie te meten, waarbij de dynamiek van gencascades tijdens ziekte en gezondheid 
in kaart kan worden gebracht. Met de ontwikkeling van betere toegepaste bioinformatica 
zullen toekomstige studies in staat zijn om de enorme hoeveelheid aan informatie die door 
genexpressie-technieken wordt gegenereerd, te stroomlijnen; dit zal hopelijk resulteren in 
een nieuwe set van biomarkers, vanuit het lab naar het ziekenhuisbed.
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